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1. Introduction - Augmenter of Liver Regeneration (ALR) 
Liver regeneration is a well-orchestrated process that is triggered by hepatocellular 
death and can be induced by toxins, viral infections or by tissue loss due to trauma or 
surgical resection [1]. The phenomenon of liver regeneration has been known since 
the myth of Prometheus who stole fire from Zeus and gave it to mankind. As a 
punishment, Zeus’s eagle would feast on Prometheus’s liver each day, and his liver 
would regrow at night until the eagle’s return [2]. 
In the early twentieth century, scientists became interested in identifying the factors 
that regulate hepatic growth and regeneration. The first scientific evidence of the 
liver’s ability to regenerate was confirmed by performing partial hepatectomy in rats 
and showing the restoration of the liver mass [3]. In 1975 LaBrecque and Pesch [4] 
prepared an extract from weanling rat livers and demonstrated that injecting this 
substance into partially hepatectomized rats stimulates liver regeneration and 
therefore named it Hepatic Stimulatory Substance (HSS). Several attempts were 
applied to further identify and characterize the molecule responsible for the 
stimulation of liver regeneration [5-7]. After progressive purification of HSS, a fraction 
with augmenting effect following a 40% hepatectomy in rats was obtained containing 
three protein bands (14, 30 and 35 kDa) [8]. The 30 kDa band was chosen for further 
sequencing and was published in 1994 by by Hagiya et al., who first coined the term 
“Augmenter of liver Regeneration, ALR” [9]. The sequenced rat protein consisted of 
125 amino acids with a molecular weight of 15 kDa under reducing conditions and 
30 kDa under non-reducing conditions [9]. The published rat sequence was then 
corrected in 1995 [10] and proposed the presence of three ATGs and therefore 
opened the possibility of multiple isoforms of ALR. Afterwards, the sequence of 
human and mouse ALR was published in 1996 [11]. Moreover, Hepatopoietin (HPO) 
was cloned and sequenced from human fetal liver tissue in 1997 and was proved to 
be identical with ALR, therefore HPO is also referred to as ALR [12]. 
ALR protein is encoded by GFER (growth factor erv1 homolog of s. cerevisiae) gene 
that consists of 3 exons and 2 introns [10, 13] and can be regulated by different 
stimuli. In this review, we aimed to systemically review the literature discussing ALR 
structure, regulation, function and clinical importance. We included original articles, 
published in English, investigating ALR, HPO or GFER and presenting a clear 
indication of ALR isoform and molecular size. This is of note and critical, since there 
are some publications using the term “ALR” as a synonym for HSS, but using, in their 
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studies, a purified protein fraction (HSS) instead of a single sequenced protein (ALR) 
(e.g. [14-16]). Furthermore, a few reports indicated that HSS has a molecular size of 
15 kDa but then claimed that ALR is different from HSS [17], without presenting a 
sequence for HSS. Due to the ambiguity about HSS protein/fraction, articles on HSS 
were only taken into consideration, if a clear indication of gene name and molecular 
size are given. 
Although a considerable size of work has been devoted to summarizing the 
knowledge on ALR (see previous reviews [1, 18, 19]), an investigation of ALR 
expression in different organs as well as delineation between the ALR isoforms and 
the function of endogenous and exogenous ALR is still missing. Therefore, we 
aspired to revise the knowledge about ALR and gather evidence of the expression of 
different ALR isoforms and the functional role of the endogenous or exogenously 
applied ALR as well as to highlight the clinical importance of this protein.  
 
2. ALR isoforms and structure 
The first gene sequence of ALR was reported in 1994 [9] and was later corrected in 
1995, where an additional G was added at position 266. This generated two 
additional in-frame ATG initiation sites and raised the possibility of different ALR 
isoforms [10]. Indeed, the expression of different ALR isoforms in mouse, rat and 
human organs has been thoroughly investigated and the existence of three isoforms 
of ALR has been shown (Table I). Furthermore, the sequence of full length ALR 
shows 74% homology to mouse ALR and 73% homology to rat ALR (Fig. 1A). The 
longest transcript of ALR encodes a 205 amino acid protein corresponding to a 
molecular weight of 23 kDa [20]. Moreover, the smallest transcript of ALR encodes a 
125 amino acid protein corresponding to a molecular weight of 15 kDa (short form 
ALR, sfALR) [13]. The sfALR is 80 amino acids shorter than lfALR at the N terminus 
[20] (Fig. 1B). Those 80 amino acids are also referred to as “N80”. N80 includes (i) N-
terminal (N-N80) domain which is described as an IDD (intrinsically disordered 
domain) and acts as a crucial targeting signal from the cytosol into the mitochondria 
[21]. (ii) C-terminal of N80 (C-N80) contains the CRAC motif (71-74 aa) (Fig. 1B). 
CRAC motif acts as a recognition site in the disulfide relay system of mitochondrial 
inter-membrane space (IMS). CRAC mediates the “recycling” of Mia40, an 
oxido-reductase, in charge of oxidative protein folding in the IMS [21-23]. Moreover, it 
was previously shown that mutating the cysteine residues (C71 or C74) in ALR’s 
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CRAC motif leads to preventing the reaction with Mia40 [23]. Nevertheless, Mia40 
can still exchange electrons with ALR through the CEEC motif (142-145 aa) 
(corresponds to CXXC motif in Erv1, yeast homologue of ALR) (Fig. 1B) but this 
exchange is less efficient due to the “buried” structure of the CEEC motif. This 
argues for a specific hydrophobicity near the CRAC motif of long form ALR that 
drives the reaction between Mia40 and the N terminus of ALR [23]. In addition, Lu et 
al. have demonstrated that interaction between ALR and JAB1 occurs via amino 
acids 81-143 (corresponds to 1 to 63 aa in sfALR) [24] (Fig. 1B). Furthermore, the 
CEEC motif (Fig. 1B) neighbors the FAD binding domain and is affected by the 
reaction between Mia40 and FAD. Moreover, the “CEEC-FAD” region of ALR is 
referred to as “redox active center” that donates electrons to Mia40 [23].  
Additionally, disulfide bonds formation in ALR (Fig. 1B) is of importance for ALR 
functionality. C95 and C204 are responsible of forming head-to-tail dimers of all 
isoforms of ALR and therefore stabilizing the structure [25]. The dimerization also 
facilitates the binding to the FAD molecule by non-covalent bonds [26, 27]. Other 
cysteins, C171 and C188 form “intramolecular” disulfide bonds that flank the FAD 
molecule. It is worth to mention that C154 and C165 (non-conserved cysteins) in 
human ALR (Fig. 1A) may account for oligomers formation ofter seen during the 
preparation of recombinant human ALR and mutating those cysteins prevented the 
formation of oligomers in recombinant human ALR [23]. 
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Fig. 1. (A) An illustration of ALR sequence homology in human, mouse and rat is shown. Sequences of rat, mouse and human ALR were obtained from Pubmed 
search tool. Dashes indicate absence of the amino acid, black frames the non-conserved cysteins and * the initial methionines. (B) The structure of human ALR 
isoforms. Long forms (23 and 21 kDa) of ALR posess additional 80 amino acids (N80) at the N terminus of the short form ALR (15 kDa). N80 harbors the IDD and 
CRAC motif, which are responsible for mitochondrial localization and Mia40 recognition. The CEEC motif (corresponds to CXXC in yeast homologue Erv1) and 
the neighboring FAD binding domain, which “recycle” Mia40 by catalyzing the electron transfer from ALR to Mia40. Disulfide bonds formed by cysteins are 
indicated by arrows; D: functional dimerization; O: Oligomerization (non-conserved cysteins) and IM: intramoleclular bonds. IDD: intrinsically disordered domain. 
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3. Regulation of ALR 
The human ALR gene (GFER) (growth factor erv1-like) has been mapped on 
chromosome 16 next to the polycystic kidney disease gene (PKD1) [28]. Analysis of 
ALR gene (Fig. 2) has shown that it consists of 3 exons and 2 introns [10, 13]. ALR 
gene promoter has been shown to be TATA-less and to have some characteristics of 
an oncogene and a growth factor [29]. It further showed an initiator-like element with 
three tandem repeats (-66, -1) [29]. It was shown that regulatory elements of ALR 
promoter might exist in the region between -447 and -49bp. interestingly, it was found 
that a putative AP1/AP4 binding site (-375, -369) is responsible for negative 
transcriptional activity of ALR by AP1 (Activator Protein 1) in HepG2 cells and AP4 
(Activator Protein 4) in COS-7 cells [30]. Additionally, it was reported that ALR 
expression could be attenuated by EGF (epidermal growth Factor) via C/EBP 
(CCAAT/enhancer binding proteins) binding to its binding site (-292, -279) within ALR 
promoter [31]. Analyzing a selected promoter region (-252, -49) from the trans-
criptional start site has shown that HNF4 (hepatocyte nuclear factor 4 alpha) binds 
to a binding site (-209, -204) and reduces ALR expression [32]. In addition, SP1 
(specific protein 1) positively regulates ALR expression by binding to its binding site 
at (-152, -145) [32]. Interestingly, a recent study including the first intron of GFER 
gene (-733 to +527 bp) [33] investigated the potential regulatory elements in the 
introns that may affect the expression of different genes [34, 35]. It was 
demonstrated that HNF4 binds at (+421, +432) to ALR promoter and induces ALR 
expression [33] despite the presence of an upstream HNF4 binding site with 
repressing activity. However, the inducing effect of HNF4 is diminished upon SHP 
(Small Heterodimer Partner) activation e.g. by bile acids [33]. Exposure of 
hepatocytes to oxidative stress induces Nrf2 (nuclear factor erythroid 2-related 
factor 2), which in turn, by binding to an anti-oxidant response element (ARE) located 
between (-27, -19), induces ALR expression [36]. Interestingly, involvement of Nrf2 in 
ALR regulation was further confirmed by studies showing ALR induction upon 
treatment with known Nrf2 inducers such as tBHQ (tertiary butylhydroquinone), HBV 
(hepatitis B virus) infection [36], phenethyl isothiocyanate and sulforaphane [37, 38]. 
In addition, FOXA2 (Forkhead Box A2, also known as HNF3) binds to a binding site 
(+276, +282) within ALR promoter inducing ALR expression and this binding is 
enhanced by IL6 [39]. Moreover, ALR is also regulated by Egr1 (early growth 
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response protein-1) that binds to its binding site (+304, +314) and induces ALR 
expression [33]. 
Furthermore, phenylbutyrate, a HDAC1 (histone deacetylase 1) inhibitor and 
demethylation reagent, was shown to induce the expression of ALR in the brain of a 
Huntington's disease mouse model [40]. This proposes the possibility that ALR could 
be regulated by histone acetylation and/or methylation [40] and therefore by 
epigenetic mechanisms [41, 42]. Additionally, MIF (macrophage Migration Inhibitory 
Factor), a pluripotent cytokine involved in cell cycle, cell proliferation and liver 
regeneration, has been demonstrated to increase the promoter activity of ALR [43]. 
Interestingly, a recent report has suggested that ALR may be regulated by miRNAs 
and showed that Toluene exposure up-regulated. miR7109-5p, which may regulate 
ALR [44]. 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Schematic illustration of ALR promoter region, transcription factors and response elements 
involved in ALR regulation. SP1, FOXA2, Egr-1 and HNF4 (+421, +432) are inducers of ALR 
expression, however, the induction by HNF4 (+421, +432) is reversed by SHP which is activated by 
bile acids. Furthermore, AP1/AP4, HNF4 (-209, -204) and C/EBPβ (induced by EGF) are repressing 
factors of ALR expression. IL6-RE-BP increases the activating effect of FOXA2 whereas ARE (-27, 
-19) induces ALR expression by binding of Nrf2 to this response element. The latter could be activated 
by HBV infection, tBHQ, sulforaphane and phenethyl isothiocyanate. Moreover, HDAC1-inhibitor 
phenylbutyrate and MIF activate the expression of ALR whereas Toluene exposure represses ALR 
expression via miR7109-5p. MIF: macrophage migration Inhibitory Factor, HDAC1: histone 
deacetylase 1, C/EBPβ: CCAAT/enhancer binding proteins. 
 
4. Location of ALR 
Expression of ALR mRNA was detected in several tissues and was found to be 
highly expressed in the liver, testis, brain and kidneys. Moreover, low levels of ALR 
mRNA were detected in the heart, muscles, spleen and lungs [10, 11]. Interestingly, it 
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was shown that mRNA expression of ALR in muscle tissues differs between males 
and females between 18 and 35 years of age [45]. A variety of studies were 
published analyzing the expression of ALR protein expression, including its isoforms 
and their respective cellular localization. Table (I) summarizes reports with detailed 
information about ALR isoform (molecular weight), organ and organelle affiliation. In 
the rat brain, ALR was found to expressed in its long forms (23 and 21 kDa) [46, 47] 
in neurons and glial cells located in the nucleus and mitochondria [47]. Furthermore, 
this was partly confirmed in a study demonstrating cytosolic expression of these 
isoforms in a human glioma cell line [48]. In addition, cytosolic expression of 15 kDa 
ALR (short form ALR, sfALR) was detected in human neuroblastoma cell lines [49]. 
All ALR isoforms (23, 21 and 15 kDa) have been identified in rat muscle tissue [46] 
and other studies performing electron microscopy demonstrated ALR localization in 
the mitochondrial inter-membrane space or associated to mitochondrial cristae in 
human muscle fibers [45, 50]. Moreover, all three ALR isoforms were detected in rat 
kidneys [46] and the short form ALR (15 kDa) expression was reported in the renal 
cortex as well as medulla of rat kidneys after injury [51, 52]. In addition, testis of 
mouse [11, 46] and rat [46] also showed positive expression of long form isoforms 
(23 and 21 kDa). However, Since ALR was first detected in the livers of weanling 
rats, the hepatic expression of ALR isoforms has been thoroughly investigated. The 
first report demonstrating ALR protein expression by Giorda et al. [11] showed 
western blots with ALR bands of 40, and 23 kDa under non-reduced conditions in rat 
and mouse liver tissue, and a 28 kDa band was also detected in rat liver. In the 
meantime, the expression of ALR under reducing conditions showed 2 bands (~23 
and ~21 kDa) in mouse [36, 53, 54] and rat [46, 54-56]. Using non-reducing 
conditions revealed expression of 3 bands (40, 38 and 36 kDa) of ALR in rats [57] 
and in normal as well as disease-mouse models (NASH and ALD) [53, 57]. 
Interestingly, in a study that used liver-specific knock-out of ALR (by an 
albumin-Cre/LoxP system) it was shown that ALR protein expression, after being 
repressed at birth, reappeared in the livers of the KO-mice after 1 year. The same 
study indicated the presence of oval cells (hepatic progenitor cells, HPC) in the 
KO-mice [57] which might explain the recurred expression of ALR by activation of 
HPCs and consequently giving rise to cholangiocytes or hepatocytes [58]. Gandhi 
and his colleagues did not describe ALR expression in cholangiocytes [53, 57, 59], 
but based on the findings that ALR is expressed in epithelial cells of the human liver, 
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both in hepatocytes and cholangiocytes [36, 60, 61], a potential expression of ALR in 
HPC might be proposed. So far, expression of ALR in non-parenchymal liver cells 
could not be detected [36, 61] except noted in one study [59] with low expression of 
ALR in stellate, Kupffer and hepatic endothelial cells, which was not detectable after 
2 days of cell culture. It is worth to mention that in human liver tissue, hepatocytes 
and hepatoma cell lines under reducing conditions ALR is expressed up to all three 
isoforms (23, 21, 15 kDa) and in several bands (40, 38, 36 kDa) under non-reducing 
conditions [57]. Furthermore, it was demonstrated that hepatoma cell lines (HepG2, 
Huh7 and Hep3B) express the 23 and 21 kDa ALR [33, 36, 54, 62] in the 
mitochondria as well as cytosol [54]. Moreover, primary human hepatocytes (PHH) 
were analyzed and showed expression of 3 isoforms of ALR in the cytosol, whereas 
23 and 21 kDa were additionally found in the mitochondria [54]. Another study by Li 
et al. using human fetal, adult normal and tumorous liver tissue reported 23 kDa ALR 
in the cytosol and its 15 kDa isoform in the nucleus [63]. In addition, expression of 
ALR was investigated in normal [54, 61, 62], HCC (hepatocellular carcinoma) [61-64], 
CCC (cholangiocellular carcinoma) [61], and HBV positive [36] liver tissue and 
demonstrated reduced ALR expression in normal liver compared to diseased tissues. 
The expression of three isoforms of ALR (23, 21, 15 kDa) is attributed most likely to 
the presence of 3 initial in-frame ATG initiation sites in ALR gene [10]. Therefore it is 
of interest to find out why more or less isoforms of ALR are expressed in different 
tissues and under conditions of disease. It was hypothesized that in rats the 22 kDa 
isoform is post-translationally modified by dimerization to form the observed 40, 38 
and 36 kDa bands under non-reducing conditions [59]. Recently published data by 
the same group showed two isoforms of ALR (22 and 20 kDa) under reducing 
conditions [53]. Considering the estimated molecular sizes on SDS-PAGE gells and 
the detection of 22 and 20 kDa bands of ALR under reducing conditions, the three 
bands (40, 38, 36 kDa), detected under non-reducing conditions, may be due to the 
formation of homo- and hetero-dimers of the 22 and 20 kDa ALR.  
Finally, contradictory evidence about the expression of ALR isoforms may be due to 
technical limitations like resolution of gels used in SDS-PAGE or the specificity and 
sensitivity of anti ALR antibodies for immune detection. For example, our group 
demonstrated the expression of a 23 kDa ALR in normal, cirrhosis, HCC and CCC 
samples under reduced conditions, but also showed multiple unresolved bands under 
non-reducing conditions [61]. Nevertheless, more recent studies of our group using 
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various new developed anti-ALR antibodies have shown that ALR is expressed in 
human liver in 3 different isoforms: 23, 21 and 15 kDa [54, 62]. Therefore, the 
variable findings in detecting ALR isoforms might in part be attributed to reduction of 
protein lysates, the quality of gel resolution and the quality of antibodies.  
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Table (I): Summary of studies investigating expression of ALR protein isoforms in different organs 
Organ Species Remarks Cell type Sub-cellular localization Isoform (kDa) References 
Brain 
Rat 
diencephalon, cerebellum, 
brainstem 
neurons, glial cells nucleus, external envelope 
of mitochondria 
23, 21 
[47] 
brain, cerebellum - - 23, 21 [46]
(1)
 
Human 
- neuroblastoma cell line 
SH-5YSY 
Cytosol 15 
[49]
(2)
 
- glioma cell line (T98G) Cytosol 23, 21 [48] 
Skeletal 
Muscle 
Rat - - - 23, 21, 15 [46] 
Human mitochondrial myopathy patients muscle fibers 
mitochondrial 
innermembrane and cristae, 
cytosol 
- [45, 50] 
Kidney Rat 
- - - 23, 21, 15 [46] 
induced expression of ALR in 
renal cortex and outer strip of 
outer medulla upon acute kidney 
injury (AKI) (Gentamicin- or I/R-
induced injury) 
renal tubular epithelial 
cells 
after AKI ALR was detected 
in the cytosol and apical 
plasma membrane 
15 [51, 52] 
induced expression of ALR after 
obstructive nephropathy 
  15 [65] 
Testis Mouse 
- - soluble, 
insoluble fractions  
40, 38, 23 
23 (n.r.)
(3)
 
[11]
(4)
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seminiferous tubules spermatogonia , elon-
gated sperm cells 
mitochondrial inner mem-
brane 
23, 21 
[46] 
Rat - - - 23, 21 [46] 
Blood 
Mouse 
blood plasma after hemorrhagic 
shock 
- - ELISA
(5)
 
[66] 
Rat 
blood from liver (negative in 
venous and arterial blood) 
- - 23, 21 
[46] 
serum after PCS (portacaval 
shunt), endotoxemia, gram-
negative sepsis 
- - ELISA
(5)
 
[66] 
serum after partial hepatectomy - - 21 [56] 
serum after partial hepatectomy - - ELISA
(5)
 [59] 
culture medium of hepatocytes 
upon TNFα, LPS, Actinomycin D 
or MMS treatment 
- - ELISA
(5)
 
[66] 
Human 
serum of patients - - ELISA
(5)
 [67] 
serum of patients - - ELISA
(5)
 [60] 
- leukemic T cells - 23 [68] 
serum of patients with various 
liver diseases 
- - ELISA
(5)
 
[69] 
- multiple Myloma cell 
line (U226) 
  23, 21  
[70] 
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Liver 
Mouse 
- - - 40, 23 (n.r.)
(3)
 [11] 
- - - 23, 21  [36] 
Liver 
normal, ALD, NASH liver tissue hepatocytes - 40, 38, 36 (n.r.)
(3)
 [57] 
normal and after EtOH feeding -   40, 38, 36 (n.r.) 
and 22, 20 (r.)
(3)
 
[53] 
- - - 22, 20 [54] 
Rat 
- - - 40, 28, 23 (n.r.)
(3)
 [11] 
- - - 23, 21 [46] 
- hepatocytes, sparely in 
non-paranchymal cells 
cytosol 40, 38, 36 (n.r.)
(3)
 
[59] 
- - cytosol 23, 21 [56] 
- - - 23, 21 [55] 
- - - 22, 20 [54] 
Human 
  hepG2 cells cytosol, perinucleus region - [24] 
human liver (fetal, adult and 
tumor) 
- cytosol, nucleus  23 (cytosol), 
15 (nucleus) 
[63] 
- hepatocytes, 
cholangiocytes 
cytosolic, perinuclear 
immunostaining  
23 
[61] 
- cell line SMMC-7721 mitochondria 23 (mitochondria), 
15 
[71]
(6)
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- hepatocytes, rarely in 
cholangiocytes and 
endothelial cells  
cytosol, negative in nucleus  -  
[60] 
  HepG2 mitochondria, cytosol 23, 21 [33, 36, 54, 62] 
Liver 
human liver samples (normal and 
HCC) 
- - 23, 21, 15 
[62] 
human liver sections (normal, 
ALD, HBV postive) 
hepatocytes and 
cholangiocytes 
- - 
[36] 
human liver sections  hepatocytes  cytosol, barely in nucleus - [64] 
human liver samples (normal, 
ALD, NASH, HCV) 
- - 40, 38, 36 (n.r.)
(3)
 
[57] 
  PHH lfALR in mitochondria, 
cytosol, sfALR in cytosol 
23, 21, 15 
[54] 
  Hep3B - 23, 21 [54] 
normal liver tissue - - 23, 21, 15 [54] 
- Huh7 - 23, 21 [54] 
Cervix Human - Hela cells mitochondria 23 [72] 
 
(1) Klissenbauer et al. have investigated the expression of ALR protein in different rat tissues, 23 kDa ALR was detected in heart. Moreover, 23 and 21 kDa ALR were detected in 
fat tissue, spleen and lungs. 
(2) Plomino et al. (2009) have pointed out the possibility of ALR up-take upon treatment with recombinant ALR (15 kDa). 
(3) (n.r.) stands for non-reduced conditions and demonstrated analysis of ALR dimers, whereas (r.) stands for analysis of ALR under reduced conditions. 
(4) Giorda et al. (1996) investigated the expression of ALR in mouse spleen and demonstrated the expression of 23 kDa ALR in soluble and insoluble fractions. 
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(5) ALR detection using ELISA includes all isoforms of ALR. 
(6) Cao et al. (2009) investigated the expression of ALR in SMMC-7721 cell line and detected 15 and 23 kDa ALR, the latter was localized in the mitochondria. Nevertheless, a 
recent report has suggested not considering the studies including BEL7402, SMMC7721 or SKHEP1 cell lines due to the highly possible contamination with Hela cells which 
was reported in different laboratories in Asia and Europe. [73]. 
 Chapter 1 
 
17 
5. Clinical importance of ALR 
5.1. Mutations in GFER gene 
Over the last years, the clinical importance of ALR has been underlined by studies 
that identified several mutations in ALR gene (GFER) (Fig. 3) leading to severe 
mitochondrial disorders. The first described mutation in ALR gene (GFER) (R194H) 
was reported to cause an infantile mitochondrial disorder [74]. Di Fonzo et al. 
reported three children who suffered from, among others, progressive myopathy, 
partial combined respiratory chain deficiency and development delays. Later on, the 
mutation (R194H) was characterized structurally and enzymologically in both lfALR 
(23 kDa) and sfALR (15 kDa) and was demonstrated to adversely affect the stability 
of both isoforms of ALR (characterized by weaker FAD binding and lower thermal 
stability) with minimal effects on its enzyme activity (characterized by minor changes 
to interaction with Mia40 and cytochrome C) [75]. However, in a more recent study it 
was emphasized that the mutated site (R194H in human ALR that corresponds to 
R182H in yeast Erv1) causes lower thermal stability and the quick release of the FAD 
cofactor but also pointed out the loss of enzyme activity (interaction with Mia40) [76]. 
Furthermore, North et al. [77] described a patient at the age of 18 months with 
neonatal onset of lactic acidosis, poor feeding, irritability, hepatomegaly, bilateral 
cataracts and adrenal insufficiency. This patient was diagnosed with a mitochondrial 
disorder, but the genetic etiology was unknown. At the age of 19 years old, the 
patient was presented with significant muscle weakness in the face, neck, trunk and 
proximal portions of all extremities [78]. Using “Next generation sequencing” (NGS) 
the R194H mutation as well as another mutation in GFER gene (Q125X; C.373C>T) 
(Fig. 3) were reported. This mutation (Q125X) was predicted to cause loss of normal 
function of ALR protein either by premature protein truncation or nonsense mediated 
mRNA decay. In addition, three further GFER mutations (C.259-25_259-24delCA, 
C.219delC, C.217delG) (Fig. 3) were identified in a study and were suggested to 
cause frame shift variations or truncation of ALR [79]. Interestingly, in a recent report, 
the authors suggested using rapid targeted genomics to analyze genetic defects in 
GFER gene in critically ill infants, since they identified R194H mutation in a 5 day old 
infant suffering from lactic acidosis and dysmorphic features [80]. This might open the 
possibility that investigating ALR mutation may contribute to adjustment of treatment 
plans and improvement in pre-symptomatic and prenatal testing.  
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Fig. 3. Schematic illustration demonstrating the localization of reported mutations in patients. 
C.217delG and C.219delC (p.(Ala73Profs*77) and p.(Cys74Alafs*76) respectively) are of truncating 
nature, C.373C>T (p.(Gln125X)) causes either premature protein truncation or non-sense mediated 
mRNA decay. C.259-25_259-24delCA causes frame shift variations and C581G>A (p.(Arg194His)) 
causes loss of stability or enzyme inactivation. Adapted from Nambots et al. 2017 [79]. 
 
5.2. ALR and liver diseases 
The mRNA and protein expression of ALR have been investigated in specific organs 
linked to various diseases and using different injury models. For example, performing 
an ischemia/reperfusion injury (IRI) in mice and a hypoxia/re-oxygenation (H/R) 
model induced expression of 15 kDa of ALR in the kidneys [51, 52, 65, 81]. Acute 
kidney injury (AKI) also induced the expression of ALR [51, 52]. Moreover, the 
expression of ALR was reported to be induced in muscle biopsies from patients with 
mitochondrial myopathies [50] and was shown to be inversely correlated with the 
tumor grading in samples from patients with colorectal carcinoma and colon cancer 
cell lines [82].  
ALR expression was thoroughly analyzed in samples from patients with various liver 
diseases (see summary in Table II) and was found to be strongly increased in 
diseases associated with normal or abnormal regeneration like cirrhosis or HCC. 
Several reports have shown that the expression of ALR is increased in liver tissue 
from patients with HCC [60-62, 83], CCC [61] and cirrhosis [61, 69, 84]. Interestingly, 
ALR protein expression in HCC correlates inversely with tumor grading and its 
angio-invasion [62, 83] and this was found presumably to be attributed to expression 
of the cytosolic 15 kDa ALR isoform (sfALR) [62]. Furthermore, ALR mRNA [54] and 
protein [57] expression were shown to be reduced in the liver of patients with 
non-alcoholic steatohepatitis (NASH). In hepatic samples from patients with alcoholic 
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liver diseases (ALD) ALR expression was either reduced [57] or not altered [36] 
compared to normal liver tissue. Moreover, ALR mRNA expression has been 
investigated in liver tissues from patients with cholestatic liver diseases and was 
found to be significantly reduced (chapter 5).  
Infection with hepatitis B virus leads to induction of several genes among them target 
genes of Nrf2 such as ALR [36]. Hence increased ALR mRNA and protein expression 
was found in HBV positive liver tissues [36]. Furthermore, ALR serum levels were 
found to be induced in patients with HBV-related acute, chronic and severe hepatitis 
or cirrhosis [69]. Serum levels of ALR might be considered a candidate for prognosis 
of HBV related-liver failure since it was found to be induced in patients with 
HBV-related ACLF (acute-on chronic liver failure) compared to normal patients and to 
be also induced in the surviving ACLF patients compared to dead patients [85]. In 
addition, patients with improved hepatic failure (HF) show increased serum levels of 
ALR protein compared to patients with deteriorating HF [60]. On the other hand, HCV 
infection impairs induction of Nrf2 [86] and therefore as expected, ALR expression is 
not altered in HCV positive liver tissue [36, 57]. Interestingly, hepatic ALR expression 
is low or even unchanged after insulting the liver by fat, alcohol or HCV infection, 
respectively. But as a consequence of these insults progression to cirrhosis or even 
tumorigenesis occurs with induction of ALR expression as part of the regenerative 
response that occurs regardless of the underlying etiology [61].  
 
5.3. ALR and in vivo models 
Multiple studies have reported the use of mouse and rat models that mimic diseases 
conditions in order to explore the effect of ALR in those diseases. It was reported that 
ALR serum levels are elevated in rats after PCS (portacaval shunt) surgery, 
endotoxemia or sepsis, and in a mouse model of hemorrhagic shock [66]. 
Furthermore, ALR serum levels are increased in rats after tissue loss by partial 
hepatectomy (PH) [56, 59] and return to normal levels after 12 hours [59] or 36 hours 
[56]. On the contrary, hepatic level of ALR after PH remains unchanged (after 40% 
PH) or decreases (after 70% PH) [59]. ALR liver-specific knock-out mice have been 
shown to endure accelerated steatosis and to develop liver tumors after 1 year [57]. 
The same mouse model was used to investigate the alcohol-induced injury and was 
shown to accelerate injury [53]. Interestingly, using hepatocytes transfected with ALR 
(23 kDa) expression plasmid have shown that endogenous ALR enhances the effect 
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of anti-tumor agents [87] and reduces IRI injury in steatotic liver [88]. Further, the 
subcutaneous-injected hepatoma cells expressing sfALR (15 kDa, [62]) or lfALR 
(23 kDa, [83]) showed reduced tumor growth in mice due to their reduced metastatic 
ability. Injecting ALR (23 kDa) expression plasmid into mice with CCl4-induced injury 
suppresses apoptosis and attenuates the acute injury [84] which is underlined with a 
study that reported increased ALR serum levels after CCl4-injury in rats [85]. 
Interestingly, ALR-knock-in and knock-out models in Zebrafish have been established 
and demonstrated the functional role of ALR in vertebrate hepatogenesis [89]. It is 
worth to mention that the physiological effects of ALR in spermatogenesis were 
investigated by an ALR transgenic mouse model driven by the human TSPY (testis-
specific protein, Y-encoded) promoter that allows the transgene to be specifically 
activated in the testes [90]. This study highlighted that temporal expression of ALR is 
required for normal testicular development and spermatogenesis. 
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Table (II): Summary of studies investigating hepatic expression of ALR in various liver diseases with the methods used in the 
investigation. 
 
Liver disease Study subject Target Methods Reference 
Hepatocellular 
carcinoma (HCC) 
HCC vs. corresponding surrounding non-tumorous tissue (n=4), HCC vs. surrounding 
cirrhotic tissue (n=5) 
mRNA PCR 
[61] 
normal vs. HCC (n=5) protein IHC, wb 
normal (n=10) vs. HCC (n=20) serum ELISA 
[60] HCC vs. HF and normal mRNA PCR 
HCC vs. HF  protein IHC 
normal (n=1) vs. HCC (w/o angioinvasion n=2 and with angioinvasion n=2) protein Wb 
[62] 
HCC liver sections (n=53) (high vs. Low expression of ALR) protein IHC 
non-tumorous (w/o HBV nor alcohol, n=5) vs. tumorous (w/o HBV nor alcohol, n=12) protein IHC [36] 
HCC (n=22) vs. para-cancerous liver tissue (n=22)  mRNA PCR 
[64] 
HCC vs. para-cancerous liver tissue protein IHC 
HCC with low ALR (n=19) vs. HCC with high ALR (n=25) mRNA PCR 
[83] HCC w/o angioinvasion (n=29) vs. HCC w angioinvasion (n=14) mRNA PCR 
HCC w/o angioinvasion (n=4) vs. HCC w angioinvasion (n=4) protein IHC, wb 
Cholangiocyte 
carcinoma (CCC) 
CCC vs. corresponding non-tumorous tissue (n=5) mRNA PCR 
[61] 
normal vs. CCC (n=3) protein IHC, wb 
Hepatitis B virus 
(HBV) infection 
normal (n=10) vs. Chronic HBV infection (n=20) serum ELISA [85] 
HCV (n=10) vs. HBV (n=10) mRNA PCR 
[36] non-tumorous with HBV (n=8) vs. tumorous (with HBV, n=7) protein IHC 
non-tumorous w/o HBV (n=5) vs. non-tumorous with HBV (n=8) protein IHC 
normal (n=10) vs. Acute (n=5), chronic (n=30) and severe (n=15) hepatitis B infection serum ELISA [69] 
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Hepatitis C virus 
(HCV) infection 
normal (n=5) vs. HCV infection (n=7) protein Wb [57] 
Non-alcoholic fatty 
liver diseases 
(NAFLD) 
normal (n=5) vs. NASH (n=5) protein Wb [57] 
normal (n=17) vs. Steatosis (n=27) and NASH (n=29) mRNA PCR [54] 
Alcoholic liver 
diseases (ALD), 
alcoholic 
steatohepatisis 
(ASH) 
non-tumorous with alcohol (n=4) vs. HCC with alcohol (n=14) protein IHC
(1)
 [36] 
normal (n=5) vs. ALD (n=5) protein Wb [57] 
Cholestatic liver 
diseases (CLD) 
normal (n=13) vs. Cholestasis (n=45) mRNA PCR chapter 5 
Hepatic failure (HF) 
and Acute liver 
diseases (ALD) 
improved HF (n=6) vs. deteriorating HF (n=12) serum ELISA [60] 
normal (n=10) vs. HBV related ACLF (n=40) serum ELISA 
[85] 
survival ACLF patients (n=10) vs. Dead ACLF patients (n=10) serum ELISA 
normal (n=2) vs. Acute liver failure (n=2) protien Wb [84] 
Cirrhosis 
normal (n=18) vs. Cirrhosis (n=25, with n=14 alcohol-induced cirrhosis, n=7 HCV-induced 
cirrhosis and n=4 autoimmune diseases induced cirrhosis) 
mRNA PCR 
[61] 
normal vs. Alcohol-induced cirrhosis (n=5) protein IHC, wb 
normal (n=10) vs. Cirrhosis (n=30) serum ELISA [69] 
normal (n=2) vs. Liver cirrhosis (n=2) protein Wb [84] 
Wb = western blot; PCR = qRT-PCR; IHC = immunohistochemistry 
(1) Dayoub et al. (2013) investigated ALR protein expression in liver sections from patients with HCC and non-tumorous tissue (with or without HBV or alcohol) by IHC and 
quantitatively evaluated the intensity of anti-ALR staining (from 0 to 3). 
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6. Function of ALR 
Different isoforms of ALR have been associated with different subcellular 
localizations and therefore specific functions. Several studies have investigated the 
role of the 23 kDa ALR (long form, lfALR) and the 15 kDa ALR (short form, sfALR) 
related to different diseases and pointed out the beneficial effects of the individual 
ALR isoforms. In the next paragraph we summarize the studies that investigated the 
over-expression of lfALR and sfALR as well as the studies that explored the impact 
of ALR silencing (effects all isoforms) on cellular functions. 
 
6.1. The functional role of mitochondrial lfALR (23 kDa) 
As implied before, the 23 kDa of ALR is located in the mitochondria (see the location 
of ALR) and the mitochondrial targeting of ALR is attributed to the IDD domain in the 
initial 80 amino acids (N80) at the N terminal of lfALR (see the structure of ALR). In 
mammalian cells, lfALR is a part of the disulfide relay system that recycles Mia40 
(mitochondrial import and assembly 40) in the inter-mitochondrial space (IMS) while 
transporting proteins into the IMS. Mia40 interacts with its substrates by its CPC 
motif [91, 92] and oxidizes those substrates which leads to substrate folding and 
trapping in the IMS. Furthermore, reduced Mia40 is re-oxidized -“recycled”- by the 
CRAC and CXXC motif in ALR, which itself obtains electrons from cytochrome C [22, 
23, 93]. For more detailed information about the role of ALR in mitochondrial 
biogenesis we would like to refer to the recent review article of Kallegri et al. 2014 
[94] and Erdogan et al. 2017 [95]. 
Besides its role in mitochondrial protein import, there has been contradictory 
evidence about the role of ALR in the maturation and export of cytosolic Fe-S cluster 
proteins. Fe-S proteins were reported to be involved in enzymatic catalysis, DNA 
synthesis and repair, iron homeostasis and heme synthesis [96]. Lange et al. [97] 
have suggested that ALR, may be involved in the maturation of cytosolic Fe-S 
proteins. The authors claimed that ALR interacts with Atm1 (an ABC transporter in 
the inner membrane of the mitochondria) and facilitates the export of Fe-S proteins 
to the cytosol [97]. However, later it was suggested that, in yeast cells, ALR plays 
neither a direct nor an indirect role in the maturation of Fe-S cluster [98]. 
Nevertheless, a recent study in mammalian cells has pointed out the role of ALR in 
exporting MitoNEEt to the outer mitochondrial membrane (OMM). MitoNEEt is a 
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Fe-S protein that is synthesized in the mitochondrial matrix. Upon synthesis, 
MitoNEEt translocates through the inner membrane (IM) of the mitochondria by 
ABCb7 and then through the IMS by ALR to the OMM where it contributes to cell 
proliferation [72]. However, whether ALR is involved in the maturation and export of 
other Fe-S protein still requires further investigations.  
Furthermore, endogenous lfALR (23 kDa) has been investigated in various disease 
models and Table (III) summarizes the studies about over-expression of lfALR and 
its role in different diseases. Expression of lfALR promotes liver growth during 
hepatogenesis [89], reduces fibrotic injury [99, 100], protects against 
radiation-induced oxidative stress [71] and attenuates acute liver injury by 
acetaminophen or CCl4 [84, 101]. The latter has been attributed to autophagy 
activation (by promoting p62 degradation and LC3II conversion) and apoptosis 
repression [84, 101]. In addition, lfALR has been reported to reduce ER stress [102] 
and promote the anti-tumor effects of doxorubicin by increasing its cellular retention 
[87]. Furthermore, lfALR has been shown to increase the pluripotency of embryonic 
stem cells (ESC) by preserving the mitochondrial integrity and function in ESCs [103] 
On the other hand, it was shown that lfALR does not contribute to reducing the bile 
acid-induced apoptosis [104].  
It is worth to mention that over-expression of lfALR in the testis of the mice 
(transgenic mouse) was reported to cause abnormal spermatogenesis and reduced 
fertility in those mice [90]. Interestingly, it was suggested that continuous 
over-expression of lfALR in mammalian cells leads to the accumulation of lfALR not 
only in the mitochondria but also in the cytosol [105]. Since no exclusive 
mitochondrial localization of lfALR is demonstrated in previously mentioned studies, 
the question rises whether the previously reported effects e.g. altering gene 
expression by endogenous lfALR may be due to its cytosolic accumulation rather 
than its mitochondrial localization.  
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Table (III): Summary of the studies investigating the over-expression of lfALR (23 kDa) 
Vehicle Host Disease / Model Function Molecular explanation Reference 
pcDNA3 injection into rat 
caudal vein 
liver fibrosis (induced 
by colchicine) 
protects against fibrosis, en-
hances regeneration 
reduces the expression of TIMP1, collagen I 
and collagen III [99] 
pcDNA3.1/ Myc-
HisB vector in 
Lentivirus 
cell lines (HepG2, 
SMMC-7721, BEL-
7402, 293FT, L02) 
radiation (oxidative 
stress) 
protects against radiation-
induced oxidative stress, 
improves cell viability 
reduces ROS production, mitochondrial 
dysfunction, apoptosis; reduction of 
cytochrome C release and caspase 3/7 activity  
[71] 
pcDNA3.1/ Myc-
HisB 
transfection into 
Huh7-NTCP cells 
cholestasis (GCDCA) no reduction of caspase 3/7 
activity 
- 
[104] 
MSCV-IHRES-GFP 
retrovirus 
transfection into 
mouse ESC 
(Embryonic stem 
cells) 
- promotes ESC pluripotency, 
preserves mitochondrial 
structural integrity and 
function 
reduces expression of Drp1 (Dynamine-
related protein 1)  
[103] 
mRNA of ALR  injection into 1-2 
cell stage Zebrafish 
embryos 
hepatogenesis promotes liver growth - 
[89] 
Minicircle vector or 
pcDNA3.1  
transfection into 
SMMC-7721, HSC-
T6 (rat hepatic stel-
late cells), injection 
into rat tail 
liver fibrosis reduces the fibrotic injury, 
increases the survival rate via 
deactivation of HSC 
- 
[100] 
Lentivirus injection into 
mouse tail 
acute liver injury by 
acetamiophen (APAP) 
over-dose (oxidative 
stress) 
protects liver by activation of 
autophagy and reduction of 
apoptosis  
increases p62 degradation and LC3II 
conversion, reduces release of AIF, 
cytochrome C and caspase 3 activation 
[101] 
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pcDNA3.0  injection in mouse 
tail or transfection 
into AML12 cells 
CCl4-induced acute liver 
injury 
protects against acute liver 
injury by autophagy induction, 
suppression of apoptosis, pro-
moting proliferation 
induces p62 degradation, LC3II conversion 
and levels of ATG5, ATG7 and Beclin-1. 
[84] 
p-Adxsi-Flag 
tagged vector 
transfection into 
HepG2 cells (xeno-
grafts in mice) 
HCC and anti-tumor 
agents (doxorubicin) 
sensitizes hepatocytes to anti-
tumor effects of doxorubicin  
reduces expression of ABCB1 and ABCG2 
(MDR proteins) partially by blocking Snail/Akt 
pathway 
[87] 
pcDNA 3.0 transfection into 
HepG2 cells 
lipotoxicity (palmitic 
acid treatment) 
reduces ER stress by 
reducing Ca
+2
 release to the 
cytosol 
reduces IP3R expression, induces IP3R and 
Bcl2 interaction, reduces mitochondrial Bax 
expression 
[102] 
flag tagged pAdxsi 
into Adenovirus 
transfection into 
mice or HepG2 
cells 
IRI liver injury and 
steatosis 
reduces inflammation and 
necrosis caused by IRI 
enhances oxygen consumption and ATP 
production [88] 
- transfection into 
MHCC97H and 
xenografts in mice 
HCC and metastasis reduces HCC metastasis  blocks ERK pathway 
[83] 
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6.2. The functional role of cytosolic sfALR (15 kDa) 
Short form ALR (sfALR, 15 kDa) is located in the cytosol [54] and presumably in the 
nucleus [63], due to the lack of the IDD (responsible for mitochondrial targeting) in 
the initial 80 amino acids (N80) found only in lfALR (see ALR structure). However, 
the potential effects (summarized in Table IV) and molecular functions (Fig. 4) of 
sfALR have been investigated in different models. sfALR was shown to induce the 
response of hepatocytes to IL6 signaling by induced STAT3 (signal transducer and 
activator of transcription 3) phosphorylation, which increases the expression of e.g. 
acute phase proteins (APP) like fibrinogen  (FGB) and haptoglobin (HP) [106]. In 
addition, the activation of STAT3 might account for the anti-apoptotic effect of sfALR 
by reduced DR5 (death receptor 5) expression and caspase 3/7 activity during 
cholestasis (chapter 5) and free fatty acid (FFA)-induced toxicity [54]. Interestingly, 
the reduced DR5 expression by sfALR may also be due to reduced CHOP (C/EBP-
homologous protein, an inducer of DR5 expression [107]) which is repressed upon 
attenuation of FFA-induced ER-stress by sfALR [54]. 
In addition, sfALR was attributed to have anti-metastatic effects by reducing the 
migratory and invasion activity of hepatoma cells and as well as maintaining an 
epithelial like state with less signs of aggressive proliferation. sfALR mediates this by 
reducing Snail expression which induces the expression of epithelial cell markers like 
CDH1 (E-Cadherin) and ZO-1 (Zona Occludens-1) [62]. Moreover, the hepatic 
metabolic capacity is affected by endogenous sfALR by reducing cholesterol 
catabolism into bile acids due to reduced CYP7A1 (rate-limiting enzyme in bile acid 
synthesis) expression and reduced HNF4α expression (chapter 5). Additionally, lipid 
metabolism genes (CPT1, FABP1, ELOVL6) were reported to have altered 
expression in sfALR over-expressing cells under steatotic conditions [54], which 
could be due to repressed activation of JNK [54, 108] or the activation of miRNA 
expression e.g. miR122 [108]. 
The interactions of sfALR protein with other molecules have been also reported in 
multiple studies (Fig. 4). Endogenous sfALR interacts with JAB1 (c-Jun-activating 
domain binding protein 1) [24, 109-111] in the nucleus and might include the whole 
CSN (COP9 signalosome, consisting of COP9 and JAB1) [111]. This interaction 
results in AP1 activation [109, 111] in a MAPK- and JNK-independent manner [24]. 
Furthermore, it was shown that ALR activation of AP1 is dependent on the CXXC 
motif in ALR [109]. Interestingly, a study in hematopoietic stem cells (HSC) demon-
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strated that binding of ALR to JAB1 blocks JAB1 interaction with p27kip1, which 
promotes cell cycle arrest and restricts the abnormal proliferation of HSC and the 
subsequent exhaustion [110]. This was confirmed by ALR knock-down that caused 
reduced p27kip1 nuclear retention and therefore a hyper-proliferative response of the 
HSC [110]. Moreover, cytosolic sfALR interacts with MIF (macrophages migration 
inhibitory factor) [43], which also results in AP1 activation due to MIF’s ability to block 
AP1 [43], this interaction might as well block MIF effects on p53 and results in tumor 
suppression [112] which may contribute to the described anti-metastatic effects of 
ALR [62]. Furthermore, ALR interacts with thioredoxin (TRX) [113] by its CXXC motif 
(C142-C145) and contributes to the maturation of viral proteins [113]. This interaction 
results in oxidized TRX which therefore induces AP1, c-Jun and NFB activity [26]. 
Additionally, ALR interacts with the pro-apoptotic protein BNIPL (Bcl-2/adenovirus 
E1B) and leads to growth inhibition in hepatoma cells (BEL-7402) [114]. 
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Table (IV): Summary of the studies investigating over-expression of sfALR (15 kDa) 
Host, traget cell Vehicle Disease/ model Function of sfALR Molecular explanation Reference 
infection of BS-C-1 
cells (Kidney) 
pTargeT vector 
controlled by T7 
promoter in 
vaccinia virus 
- interacts with thioredoxin interacts with thioredoxin (TRX) by the CXXC 
motif 
[113] 
transfection into 
COS-7 and HepG2 
cells 
pAS vector - increases c-Jun 
phosphorylation and AP-1 
activation 
interacts with JAB1 (c-Jun activation domain-
binding protein 1) in the nucleus, activates 
AP1 independent of MAPK, activates c-Jun 
independent of ERK1/2 and JNK pathways  
[24] 
transfection into 
COS-7 cells 
pCMV-Myc vector   activates AP1 interacts with JAB1 and activates AP1 via the 
CXXC motif  
[109] 
transfection into 
BEL-7402 cells 
pGEX-5x-1 vector - interacts with BNIPL 
(apoptotic protein)  
- 
[114] 
transfection into 
yeast cells and 
HepG2 cells 
pAS2-1, pACT2 or 
pFlag-CMV-2 
vector 
- activates AP1 interacts with MIF in the cytosol  
[43] 
transfection into 
COS-7 and HepG2 
cells 
pCMV-Myc vector - activates AP1 interacts with JAB1 which activates AP1 in a 
MAPK independent manner [111] 
transfection into 
COS-7 cells and 
Yeast Y190 cells 
pcDNA3.1A, 
pEGFP, pGEX-4T, 
pFlag-CMV or pAS 
vectors 
- activates AP1, NFB and c-
Jun phosphorylation 
interacts with thioredoxin  
[26] 
Intravenous 
injection into rats 
after CCl4-induced 
liver injury  
pcDNA3.1 vector acute hepatic injury, 
hepatic failure 
increases cell proliferation and 
survival rates  
- 
[115] 
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transfection into 
HSC 
(hematopoietic 
stem cells) 
murine stem cell 
virus (MSCV) 
- restricts abnormal proliferation 
of HSC 
interacts with JAB1 and inhibits the JAB1-
p27
kip1 
interaction  
[110] 
transfection into 
HepG2 cells  
pcDNA3.1 vector HCC and metastasis reduces cell motility and EMT 
(epithelial mesenchymal 
transition) 
reduces Snail expression, induces 
E-Cadherin and ZO-1 expression [62] 
mice on MCD diet  pcDNA3.1 vector NAFLD reduces the severity of fatty 
acid injury 
suppresses JNK phosphorylation and fatty 
acid synthesis genes, induces miR122 levels 
[108] 
transfection into 
HepG2 cells  
pcDNA3.1 vector acute phase response 
(APR) 
induces expression of APP: 
fibrinogen β and haptoglobin 
induces STAT3 phosphorylation  
[106] 
transfection into 
HepG2 and Huh7 
cells 
pcDNA3.1 vector NAFLD attenuates ER stress and 
lipoapoptsis, alters lipid 
metabolism genes, reduces 
TAG levels 
reduces DR5, Bax and CHOP expression 
and JNK phosphrylation, increases ATP 
synthesis, alters expression of CPT1α, 
FABP1 and ELOVL6 
[54] 
transfection into 
HepG2 cells  
pcDNA3.1 vector cholestasis reduces bile acid synthesis 
and bile acid-induced 
apoptosis 
preserves STAT3 activation, reduces HNF4α 
and DR5 expression chapter 5 
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Fig. 4. An illustration of how endogenously expressed sfALR affects hepatocytes. ALR promotes IL6 signaling by increasing STAT3 phosphorylation and thereby 
regulating STAT3 target genes. Furthermore, STAT3 activation by sfALR blocks HNF4 and reduces its trans-activating effects. sfALR also reduces the 
expression of SNAIL and CHOP (by reducing ER stress) and thereby their target genes. ALR interacts with MIF and blocks its inhibitory effects on p53 and AP1, 
which results their activation and tumor suppression by p53. ALR also interacts with thioredoxin and promotes AP1 and NFB activation. Moreover, ALR interacts 
with JAB1 in the nucleus and thereby activates AP1. MIF and thioredoxin bind to JAB1 to prevent JAB1 interaction with p27
kip1
 which increases the nuclear 
retention of p23
kip1
 and therefore induces cell cycle arrest at G1 phase. In addition, the pro-apoptotic protein BNIPL interacts with ALR and MIF and regulates cell 
survival. BNIPL: Bcl-2/adenovirus E1B, MIF: macrophage migration inhibitory factor, CHOP: C/EBP-homologous protein, STAT3: signal transducer and activator 
of transcription 3, TRX: thioredoxin, JAB1: c-Jun-activating domain binding protein 1, CSN5: COP9 signalosome subunit 5, HNF4: hepatocyte nuclear factor 4 
alpha, AP1: Activator protein 1. 
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6.3. ALR silencing 
In order to further clarify the role of ALR for cellular functions, many studies have 
explored the effect of ALR silencing (all isoforms) and monitored the outcome of its 
absence on the development of various diseases. Table (V) summarizes the main 
finding of the studies that inspected the effect of silencing ALR.  
In the kidney, it was shown that ALR knock-down had no effect on HK-2 cells viability 
[81, 116] but aggravated the H/R injury by increased ROS production and apoptosis 
due to the activation on AMPK/mTOR pathway [116]. Morevoer, ALR silencing 
inhibited cytokine production and the inflammatory response after H/R injury by 
blocking MAPK pathway [81]. Furthermore, it was suggested that ALR silencing 
decreases NKB nuclear translocation in kidney cells [81]. On the contrary, it was 
reported that over-expression of sfALR (15 kDa isoform) does not affect NFB’s 
nuclear translocation in hepatocytes during cholestasis (chapter 5), which might 
argue for organ specific effects of ALR or more likely for a specific role of different 
ALR isoforms due to their location and function. 
The anti-oxidative role of ALR was further evidenced in human derived glioma cells 
(T98G) which showed that silencing of ALR reduces the expression of anti-oxidative 
protein clusterin and induces the activity of caspase 3 and 9 [48]. Additionally, ALR 
silencing sensitizes HepG2 cells to radiation-induced oxidative stress [71]. ALR 
silencing suppresses liver growth [89], reduces cell viability and induces apoptosis in 
rat hepatocytes [117] as well as HepG2 cells [118]. In the liver, after partial 
hepatectomy ALR silencing resulted in reduced compensatory hepatocellular 
proliferation, increased pro-apoptotic proteins and caspase activity [55]. Furthermore, 
liver specific ALR knock-out (KO) mice developed steatosis accompanied by altered 
expression of lipid metabolism genes, enhanced ROS production, mitochondrial 
dysfunction, increased Bax expression and NK as well as CD8+ cell recruitment to 
the liver [57]. Interestingly, it was shown that ALR-KO mice develop liver tumors 
within 6 months of age and therefore ALR silencing links non-alcoholic liver disease 
to hepato-carcinogenesis [57]. The same group showed later that ALR-KO mice 
suffer accelerated alcohol injury, which they attributed to changes in lipid metabolism 
genes, altered alcohol metabolism by ADH1 (alcohol dehydrogenase 1), ALDH1 
(aldehyde dehydrogenase 1) and CYP2E1 (cytochrome P450 2E1) and augmented 
oxidative stress upon injury [53]. In addition, it was shown that diminishing ALR 
expression enhances free fatty acid-induced ER stress and lipoapoptosis [102] and 
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reduces the anti-tumor effects of doxorubicin due to enhanced expression of export 
transporters and therefore reduced cellular retention of doxorubicin [87]. In contrast 
to Tang et al. [118], who showed reduced tumor growth of HepG2 in nude mice after 
ALR silencing, others reported promoted cell growth and EMT (epithelial 
mesenchymal transition) [83]. It is worth to mention that silencing ALR in HSC 
(Hematopoietic stem cells) caused a hyper-proliferative response due to reduced 
JAB1 binding and therefore reduced nuclear retention of p27kip1 [110]. In addition, 
ALR silencing in mouse embryonic stem cells (ESC) increases Drp1 (Dynamine-
related protein 1) expression and activates mitochondrial autophagy, which results in 
enhanced apoptosis of ESC [119]. Interestingly, a chemical screen identified a 
molecule that is capable of inhibiting ALR activity, MitoBloCK-6 [120]. MitoBloCK-6 
was shown to induce apoptosis by cytochrome C release in ESCs but not in 
differentiated cells which suggests a vital role of ALR in the ESC homeostasis [120]. 
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Table (V): Summary of studies investigating ALR silencing (all ALR isoforms) 
Organ 
Host Vehicle disease/ 
model 
Effect of ALR silencing molecular explaination Reference 
Liver 
rat heptocytes antisense oligo-
nucleotide 
hepatocytes 
survival 
reduced cell viability and induced 
apoptosis 
induced rounding, detachment of cells, 
increased LDH and cytochrome C re-
lease, Caspase 3 activity, reduced ATP 
[117] 
HepG2, L02 cells lentivirus with 
shRNA 
radiation 
(oxidative 
stress) 
inhibited cell viability, induced sensibility 
to radiation (HepG2), minimal effects on 
normal cell line 
- [71] 
HepG2 cells, 
xenografts in 
nude mice 
siRNA in 
pSIALR-A 
plasmid 
HCC growth inhibited growth in HepG2 and xeno-
grafted HCC tumors in nude mice 
- [118] 
Zebrafish 
embryos 
Morpholino 
antisense 
oligonucleotides 
hepatogenesi
s 
suppressed liver growth reduced hepatocyte proliferation without 
affecting apoptosis 
[89] 
HepG2 cells (and 
xenografts in 
mice) 
shRNA doxorubicin 
treatment 
reduced caspase 3 activity due to 
reduced cellular retention of doxorubicin 
induced snail and therefore ABCB1 and 
ABCG2 (export pump) expression 
[87] 
HepG2, Huh7, 
Huh7-sfALR cells 
siRNA - reduced expression of the three 
isoforms of ALR 
- [54] 
HepG2 cells PLVX- shRNA-
plasmid 
lipotoxicity 
(palmitic acid 
treatment) 
induced ER stress by increasing Ca
+2
 
release into the cytosol 
induced expression of IP3R and Bax, 
reduced expression of Bcl2 
[102] 
HepG2, MHCC-
97H cells xeno-
grafts in mice 
shRNA  HCC and 
metastasis 
promoted cell growth and migration in 
vivo and in vitro 
induced EMT in hepatoma cells due to 
activated ERK pathway 
[83] 
rat adenovirus with partial reduced hepatocyte proliferation and - [55] 
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shRNA hepatectomy polyamine synthesis, increased pro-
apoptotic proteins and caspase activity 
Liver 
mice liver-specific ALR 
knock out 
(Albumin Cre-
lox) 
Steatosis ALR-KO in mice results in accelerated 
hepatic steatosis after 2 weeks, 
development of liver tumors after 6 
months of age 
increased ratio of Bax /Bcl2, induced 
IL1, TNFα and IL6, increased recruit-
ment of NK cells and CD8
+
 cells, in-
creased ROS, mtDNA damage, re-
duced ATP levels and expression of 
ACACA, SREBP1c, CPT1α and PPARα  
[57] 
mice liver-specific ALR 
knock out 
(Albumin Cre-
lox) 
alcohol 
induced injury 
accelerated alcohol induced liver injury 
in ALR-KO mice 
reduced expression of FASN, ACACA, 
SREBP1c, CPT1α (lipid metabolism 
genes), and activity of ADH1, ALDH1 
and CYP2E1 (alcohol metabolism 
genes), augmented oxidative stress, 
fibrosis, inflammation by EtOH feeding 
[53] 
Stem 
cells 
murine ESC 
(Embryonic stem 
cells) 
FG12-Lentivirus–
GFP–shRNA 
- loss of mitochondrial function in ESC, 
reduced proliferation and enhanced 
apoptosis  
triggered mitochondrial autophagy or 
mitophagy by increased Drp1 
(Dynamine-related protein 1) 
[119] 
hematopoietic 
stem cells, bone 
marrow trans-
plantation in 
mice 
FG12-Lentivirus–
GFP–shRNA 
- hyper-proliferative response and 
exhaustion in hematopoietic stem cells 
(HSC) 
reduced p27kip1 expression through its 
binding to JAB1 
[110] 
ESC, Hela cells, 
and Zebrafish 
embryos 
MitoBloCK-6 
(„ALR inhibitor“) 
- induced apoptosis by cytochrome C 
release and impaired cardiac 
development in Zebrafish embryos 
Inhibition of ALR activity 
[120] 
HK-2 cells lentivirus with 
shRNA/ALR 
H/R injury no effect on viability, inhibited 
inflammatory response and cytokines 
production after H/R injury 
blocked MAPK pathway and decreased 
nuclear translocation of NFB  
[81] 
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HK-2 cells lentivirus with 
shRNA/ALR 
I/R kidney 
injury 
no effect on cell viability, increased 
autophgy and ROS production in vitro 
activated AMPK/mTOR pathway [116] 
Glioma 
cells 
T98G cells 
(human) 
siRNA H2O2 
(oxidative 
stress) 
reduced expression of clusterin (anti-
oxidative protein) and Bcl2, induced 
Caspase 3 and 9 activity 
- [48] 
Myeloma 
cells 
U266 cells shRNA - promoted apoptosis induced Bax expression, reduced Bcl2 
expression and IL6 synthesis 
[70] 
 
 Chapter 1 
 
37 
6.4. The functional role of exogenous ALR (recombinant ALR, rALR) 
Although the current emphasis is placed on the development of “gene therapy” for 
human diseases, the production and use of recombinant proteins have a great 
impact on genetic diseases due to improvements in production of these biomolecules 
as well as their availability [121]. Therefore in this paragraph we will summarize the 
effects and action of recombinant ALR (rALR) application in different injury models 
(Table VI).  
Studies in the kidneys showed that application of rALR attenuates the injury after IR 
(ischemia reperfusion) [51, 81, 122-124] and after gentamicin application [52]. It was 
suggested that the activation of PI3k/Akt (phosphoinositide 3-kinase/ Akt) by ALR 
reduces p53 phosphorylation and increases Bcl2/Bax ratio and therefore reduces 
apoptosis [123]. Furthermore, ALR signaling represses the activity of NFB in the 
kidneys [122, 124, 125] which reduces the production of pro-inflammatory cytokines 
like IL6 and IL1 [122, 124]. ALR was also reported to reduce renal fibrosis by 
modulating the TGF1 signaling and reducing EMT in renal tubular cells [125]. 
Moreover, in human derived glioma [48] and neuroblastoma cells [49] it was shown 
that rALR attenuates H2O2-induced injury by reducing reactive oxygen species (ROS) 
and cytochrome C release, which leads to reduced apoptosis. In addition a similar 
outcome of ALR is seen on concanavalin A-treated human lymphocytes [126] with 
reduced apoptosis. Interestingly, rALR could also contribute to survival of 
transplanted hepatocytes [127] and liver after transplantation [128] by modulating the 
inflammatory response as well as reducing the production of pro-inflammatory 
cytokines [127, 128]. It is worth to mention that application of rALR upon liver 
transplantation reduces the renal tubular injury by repressing the expression of the 
pro-inflammatory TNF [129]. In addition, Adam et al. have shown that application of 
rALR reverses diabetes in the pancreas of fetal rats upon transplantation [130].  
Previous reports have focused on analyzing the impact of rALR on the liver and how 
rALR transduces its signals in liver cells (Fig. 5). The augmenting effect of rALR in 
liver regeneration was proposed by reduced activity (killing ability) of natural killer 
(NK) cells after rALR treatment [67, 131] and subsequently enhanced survival of 
hepatocytes after injury [67]. Further, rALR treatment of Kupffer cells has been 
shown to activate NFB signaling and to induce the synthesis of IL6 and TNF [132]. 
The authors found an ALR specific- and cholera toxin sensitive- receptor on Kupffer 
cells may be responsible for rALR effect on liver regeneration after 40% partial 
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hepatectomy [132]. On the other hand, there have been contradictory reports about 
the expression of an ALR receptor (ALR-R) on hepatocytes [59, 133]. Whereas on rat 
hepatocytes, no ALR receptor could be found so far [59], on human hepatoma cells it 
was shown that ALR binds to its receptor (ALR-R, not sequenced yet) and activates 
the EGF receptor on the cytoplasmatic side [133]. This results in the activation of 
EGF-R pathways via MAPK activation [134] and subsequently AP1 activation [109]. 
Upon activation of the MAPK pathway, rALR increases polyamines synthesis, a 
prerequisite for liver regeneration, by increasing the expression of c-myc and ODC 
(ornithine-decarboxylase), the rate-limiting enzyme of polyamine synthesis [135]. 
Moreover, after rALR treatment, primary human hepatocytes show increased 
proliferation, but reduced expression and activity of various cytochrome P450 [136], 
which might be mediated by activated NFB ([136], chapter 6). Later on, it was 
reported that rALR activates the PI3k/Akt pathway and was shown to induce different 
kinetics from EGF [137]. Interestingly, a recent study have investigated the role of 
rALR in modulating the IL6 signaling pathway and the acute phase response (APR) 
[106] by reducing the activation of STAT3 and subsequently the expression of acute 
phase response proteins (APP) [106]. 
The anti-apoptotic effect of rALR has been demonstrated in different injury models in 
the liver. It was shown that rALR reduces caspase 3/7 activity after free fatty acid- 
[54] and bile acid-induced injury (chapter 6), which may be due to reduced 
expression of Bax and therefore preserving mitochondrial integrity [54]. Furthermore, 
rALR reduces EtOH- and death ligand-induced apoptosis by reducing cytochrome C 
release [138]. This was further confirmed in a study showing that rALR reduces cell 
damage after partial hepatectomy by inducing the expression of anti-oxidative 
clusterin and anti-apoptotic Bcl2 and suggested that rALR boosts liver regeneration 
by attenuating apoptosis rather that inducing proliferation [56]. In addition, besides its 
immune-modulating effect, anti-apoptotic effects of rALR may account for the 
reduced liver injury upon IRI [139] and bile duct ligation (BDL), a common model of 
cholestatis [140]. 
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Table (VI) Summary of the studies investigating the role of recombinant ALR (15 kDa) 
Organ Effect of rALR Remarks Reference 
Liver 
reduces NK ability of direct and indirect killing - [131] 
no receptors of ALR on rat hepatocytes  - [59] 
ALR has a receptor on human hepatocytes (ALR-R) detection of a 75 kDa band interacting with rALR [133] 
ALR-R binds to ALR-R, activates EGF-R signaling and subsequently 
MAPK pathway 
- [134] 
protects against liver injury by inhibition of hepatic natural killer cell 
activity  
- [67] 
activates AP1  activates MAPK pathway [109] 
induces polyamines synthesis activates EGF-R signaling pathway and c-myc expression [135] 
reduces expression, activity of cytochrome P450 enzymes  activates NFB, reduces CAR expression [136] 
does not induce DNA synthesis in isolated rat hepatocytes - [117] 
reduces apoptosis (extrinsic induced, EtOH). - [138] 
affects its receptor and activates PI3k/Akt signaling pathway - [137] 
promotes liver regeneration in rats after 40% partial hepatectomy 
(PH) (not in 70% PH rats) 
binds to its cholera toxin-sensetive receptor on Kupffer cells, 
activates NFκB, induces the expression and release of 
TNFα, IL6 and iNOS 
[132] 
anti-apoptotic effects, reduced cell damage after PH reduces Bax expression, induces Bcl2, clusterin expression [56] 
promotes hepatocytes regeneration, attenuates acute injury, 
suppresses immunological responses, improves survival after 
reduces pro-inflammatory cytokines (IL1 and TNFα), [127] 
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hepatocytes transplantation reduces apoptosis and CD4
+
 recruitment  
Liver 
Reduces hepatic ischemia reperfusion injury (IRI)  
reduces the serum transaminases, reduces apoptosis and 
infiltration of inflammatory cells (neutrophiles) 
[139] 
attenuates the injury after obstructive cholestasis (BDL) reduces hepatic transaminase, preserves mitochondrail DNA [140] 
induces survival and reduced organ rejection after liver 
transplantation in rats 
reduces IL2 and IFNγ expression, promotes T cell apoptosis, 
reduces TNFα expression, induces IL10 expression  
[128] 
reduces acute phase response and the expression of acute phase 
proteins  
reduces STAT3 phoshorylation [106] 
reduces lipoapoptosis 
reduces expression of pro-apoptotic protein Bax, reduces 
caspase 3/7 activity, no effect on DR5 expression 
[54] 
reduced bile acid synthesis and bile acid-induced apoptosis  
activates NFB, reduces CAR expression, reduces CYP7A1 
expression, reduces caspase 3/7 activity 
chapter 6 
Kidney 
attenuates renal tubular epithelial cell injury after liver transplantation 
in rats 
reduces TNFα production, increases regenerating cells  [129] 
reduces gentamicin induced injury, improves renal dysfunction - [52] 
reduces tubular injury after I/R injury in rats - [51] 
attenuated renal dysfunction and injury after IRI in rats 
activates PI3k/Akt pathway, increases Bcl2/Bax ratio, 
represses p53 activation 
[123] 
attenuates the inflammatory response after hypoxia / reperfusion 
(H/R) injury 
reduces expression of IL1 and IL6 by down-regulation of 
TLR4 and NFκB expression 
[122] 
reduces renal fibrosis  
represses TGF-receptor II, alleviates TGF1 signaling, 
reduces Smad2 and NFκB phosphorylation, reduces EMT 
(epithelial mesenchymal transition) in renal tubular cells 
[125] 
attenuates I/R injury in rats reduces apoptosis and cytokine production, inhibits NFB [124] 
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improves renal dysfunction after acute kidney injury (AKI) - [81] 
Glioma cells 
(human) 
reduces H2O2-induced oxidative stress in human glioma cells reduces ROS production [48] 
Neuro-
blastoma  
induces cell viability after H2O2 injury and preserves mitochondrial 
integrity 
reduces cytochrome C release  [49] 
Pancreas reverses diabetes in fetal rodent upon pancreas transplantation - [130] 
Human 
Lymphocytes 
represses concanavalin A-induced apoptosis in activated 
lymphocytes 
reduces PARP cleavage, decreases Bax/Bcl2 ratio, reduces 
cytochrome C release 
[126] 
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Fig. 5. An illustration of how exogenous ALR affects the liver. ALR binds to its cholera toxin-sensitive 
G-protein-coupled high affinity receptor on Kupffer cells to activate NFB and increases the 
expression and release of NO, TNF and IL6. Furthermore, ALR binds to its receptor (approx. 75 kDa) 
on hepatocytes and after phosphorylation of EGF-R on cytoplasmatic Tyrosin sites, EGF-R signaling 
pathways PI3k/Akt and MAPK are activated. Activation of PI3k/Akt induces NFB, attenuates Bax 
expression leading to reduced apoptosis and represses CAR expression and subsequently less target 
gene expression. Moreover, phosphorylated MAPK reduces STAT3 activation, activates AP1 and 
c-myc expression, which leads to increased ODC expression and therefore enhanced polyamine 
concentrations. NO: Nitric oxide, TNFα: Tumor necrosis factor alpha, IL6: Interleukin 6, ODC: 
Ornithine decarboxylase, PI3K/Akt: phosphoinositide 3-kinase/ Akt, CAR: Constitutive androstane 
receptor, AP1: Activator Protein 1, PDK1: phosphoinositide dependent kinase-1. 
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Cholestatic liver injury is initiated with the hepatic accumulation of bile acids and 
leads to hepatocyte injury that manifests in ER-stress, oxidative stress and 
apoptosis. Furthermore, the inflammatory response during cholestasis is involved in 
modulating the injury. If cholestasis persists, it might result in liver fibrosis, cirrhosis 
and eventually liver failure. Augmenter of Liver Regeneration (ALR) has been proved 
to have beneficial effects on cells under oxidative stress or apoptosis. Moreover, ALR 
is a liver-specific proliferation-augmenting factor. Therefore, the targeting of such an 
organ-specific hepatoprotective factor could have great clinical importance in 
reducing the detrimental effects of bile acids on hepatocytes during cholestasis.  
The aim of this thesis was to shed some light on the regulation of ALR expression 
under circumstances of cholestasis in an in vitro model notably by bile acids as well 
as cholestasis-related cytokines and to identify the factors controlling ALR expression 
on a transcriptional level. In addition, a cohort of liver samples collected from patients 
with cholestasis was analyzed to determine the expression of ALR under cholestatic 
conditions.  
Furthermore, we aimed to elucidate the effect of ALR on the causes and outcomes of 
cholestatic injury and to explain the mechanism through which ALR attenuates bile 
acid-induced injury. 
The goals of this study could be summarized in the following points:   
 
Analysis of ALR regulation by bile acids, bile acid-induced transcription factors 
and cholestasis-related cytokines such as IL1: 
 Regulation of ALR expression by bile acids through binding motive “Bile Acid 
Response Element” (BARE). 
 Regulation of ALR expression by bile acid-induced transcription factor Egr-1. 
 Regulation of ALR expression by HNF41 and SHP interplay. 
 Regulation of ALR expression by IL1 via transcription factor SP1. 
 Role of Egr-1 in regulating ALR expression in the presence of IL1. 
 
Analysis of how over-expressed sfALR (short form ALR) affects cholestatic 
liver injury: 
 Impact of sfALR on de novo synthesis of bile acids by classical and acidic 
pathway: regulation of CYP7A1 and CYP27A1 expression and activity by 
cytosolic sfALR. 
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 Role of cytosolic sfALR on expression of transcription factor HNF4α. 
 Analysis of sfALR impact on bile acid-induced apoptosis and effector caspases in 
liver cells. 
 Regulation of death receptor expression by endogenous sfALR: DR4, DR5 and 
FASR. 
 Analysis of ALR expression in liver tissue from cholestasis patients. 
 
Analysis of how exogenously-applied rhALR (recombinant human ALR, 15 kDa) 
impacts cholestatic liver injury: 
 Impact of rhALR on de novo synthesis of bile acids by classical and acidic 
pathway: regulation of CYP7A1 and CYP27A1 by rhALR. 
 Regulation of transcription factors FXR, SHP and HNF4 by rhALR. 
 Regulation of the nuclear receptor CAR (CYP7A1 inducer and mediator of 
apoptosis) by rhALR. 
 Effect of rhALR on bile acid-induced apoptosis and expression of DR5. 
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Abstract 
Bile acids (BA) are signaling molecules that activate nuclear factors and g-protein 
coupled receptors signaling to maintain metabolic homeostasis. However, 
accumulation of toxic BA promotes liver injury by initiating inflammation, inducing 
apoptosis and causing oxidative stress leading to cirrhosis and liver failure. 
Augmenter of Liver Regeneration (ALR) is a hepatotrophic growth factor with anti-
apoptotic and anti-oxidative properties that has been shown to improve mitochondrial 
and hepatic functions in rats after bile duct ligation. In the current study we aimed to 
analyze the regulation of the pro-survival protein, ALR, under conditions of cytotoxic 
concentrations of BA. Promoter studies of ALR (−733/+527 bp) revealed potential 
binding sites for various transcription factors like Egr-1, HNF4α and two bile acid 
response elements (BARE). Using a full-length and several truncated promoter 
constructs for ALR we analyzed promoter activity and showed that BA reduce ALR 
promoter activity whereas Egr-1 transfection induces it. EMSA and supershift 
analysis confirmed the specific binding of Egr-1 to its response element within ALR 
promoter and this binding was reduced upon simultaneous stimulation with BA. We 
also showed that ALR promoter activity and protein expression are induced by 
HNF4α1 and repressed by SHP. In conclusion, these results indicate that BA 
negatively regulate ALR expression by SHP activation. 
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1. Introduction 
Bile acids are synthesized and excreted from hepatocytes into the bile and then into 
the duodenum where they act as amphiphilic agents to facilitate lipids absorption [1]. 
Bile acids have also gained great attention over the last two decades as important 
signaling molecules that regulate different metabolic process [2]. 
The synthesis of bile acids is the main catabolism pathway for cholesterol and is 
tightly controlled by regulating the expression of the synthesis enzymes [3]. CYP7A1, 
also known as cholesterol 7-hydroxylase, is the rate-limiting enzyme of Bile acids 
de novo synthesis, and is regulated by bile acids through “Bile Acid Response 
Element I” (BARE I) and BARE II [4, 5]. Several transcription factors bind to BAREs, 
for instance, HNF4 (hepatocyte nuclear factor 4α) binds to BARE II activating 
CYP7A1 expression. Upon accumulation, bile acids bind to the nuclear receptor FXR 
(Farnesoid X Receptor) which activates SHP (Small Heterodimer Partner). 
Subsequently, SHP interacts with HNF4α and represses its transactivating action [6, 
7]. 
Gallstones, local tumors and genetic deficiencies in bile acids transport proteins 
amongst others are common causes of cholestatic liver diseases [8, 9]. By definition, 
cholestasis represents pathophysiologic syndromes defined as an impaired bile flow 
from the liver. As an outcome, toxic bile acids accumulate and promote hepatocytes 
injury followed by the development of liver cirrhosis and liver failure [10]. The 
molecular mechanism of injury by bile acids has been thoroughly analyzed. bile acids 
activate the expression of Egr-1 (early growth response protein-1), a zinc finger 
transcription factor, that activates the expression of chemotactic agents leading to 
accumulation of inflammatory cells and subsequently liver injury [11]. Furthermore, 
bile acids induce apoptosis in a death receptor-dependent mechanism [12, 13] and 
manipulate the mitochondrial membrane stability by oxidative stress and ROS 
(reactive oxygen species) production [14]. Moreover, in vitro and in vivo studies have 
demonstrated that toxic bile acids induce the Nuclear factor erythroid-2 like factor 2 
(Nrf2) target genes to enhance cell survival [15]. 
Augmenter of Liver Regeneration (ALR) is a heptotrophic growth factor that was 
found to be expressed in parenchymal liver cells (hepatocytes and cholangiocytes) 
[16]. Moreover, ALR is a member of the ALR/Erv1 protein family with a flavin adenine 
dinucleotide (FAD)-linked sulfhydryl oxidase activity [17]. It was reported that the 
promoter region of ALR is TATA-less and has some characteristics of an oncogene 
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and growth factor [18]. ALR possess proliferation-augmenting properties which are 
attributed to its ability to activate the epidermal growth factor receptor (EGF-R) and 
the subsequent MAPK (mitogen-activated protein kinase) /Erk (extracellular signal-
regulated Kinase) [19] and PI3K/Akt pathways [20]. Furthermore, ALR reduces 
lipoapoptosis caused by free fatty acids [21] and acts as an anti-apoptotic/ cell 
survival factor in hepatoma cells after oxidative stress injuries [22, 23]. A recent study 
by our group have shown that exposure of hepatic cells to oxidative stress activates 
Nrf2 which in turn activates ALR expression [24]. On the other hand, FOXA2 
(Forkhead Box A2) binds to its response element within ALR promoter and activates 
ALR expression [25]. Since ALR was shown to reduce serum transaminases and 
preserve mitochondrial DNA in bile duct-ligated rats [26], we aimed to analyze the 
potential regulation of ALR under conditions of toxic concentrations of bile acids and 
to identify the transcription factors involved in the regulation of ALR expression. 
 
2. Materials and methods 
2.1. Cell culture 
Human hepatoma cell lines HepG2 and Huh7 [24] cells were grown at 37°C, 5% CO2 
in DMEM (BioWhittaker, Verviers, Belgium) supplemented with penicillin 
(100 units/ml), streptomycin (10 μg/ml) and 10% fetal calf serum (Biochrom, Berlin, 
Germany). HepG2-NTCP cells were previously described [27] and kindly provided by 
Prof. Dr. Dieter Häussinger and Verena Keitel. For Luciferase and expression 
experiments, cells were cultured at a density of 5x104 cells/cm2 and treated with 100 
or 200 µM deoxycholic acid (DCA) (Sigma-Aldrich, St. Louis, MO) for 24 hours. 
 
2.2. Promoter constructs 
Two constructs of the human ALR promoter (NC_000016.9) (-733/+240, -733/+527) 
were previously generated [25]. For ALR promoter constructs (-733/-58, -733/+493), 
the genomic sequence of ALR published earlier [28] was used and a forward primer 
containing the restriction site for BglII was designed 
(5’-atagatctcgcaaggaggcacaggaatccc-3’). Reverse primers were designed containing 
HindIII restriction site (5‘-ataagctttccaggccagcgcgcggccacag-3’ and 
5’-ataagctttccgaacaaaggcgcccaaagct-3’). Human genomic DNA isolated from 
leukocytes using the Qiamp blood kit (Qiagen, Hilden, Germany) served as a 
template. For the amplification of the promoter sequence, Taq PCR Core Kit (Qiagen, 
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Hilden, Germany) was used according to manufacturer’s instructions. Reporter gene 
constructs were cloned by ligation of PCR fragments into the BglII and HindIII 
restriction sites of the pGL2-basic vector. The identity of the subcloned DNA 
fragments was confirmed by DNA sequencing. 
 
2.3. Transient transfection and reporter gene assays 
HepG2-NTCP, HepG2 and Huh7 cells were transfected using Lipofectamine® 3000 
(ThermoFisher Scientific, Darmstadt, Germany) with an ALR promoter construct and 
either pcDNA3.1, pcDNA3.1-Egr-1 expression plasmid, pCMV-3xflag-dnEgr-1 
expression plasmid (a generous gift from Xiaojia Chen, China), or pcDNA3.1-SHP, 
pcDNA3.1-HNF41 or pcDNA3.1-HNF47 expression plasmids (received thankfully 
from Dr. Oliver Burk, Stuttgart). Dual luciferase assays were carried out 24 hours 
after transfection using dual luciferase reporter assay system (Promega, Mannheim, 
Germany). pRL-TK Renilla-vector was co-transfected to determine transfection 
efficiency and the promoterless vector pGL2-basic served as negative control. Short 
form ALR (sfALR) expression plasmid was previously generated [21]. Each 
experiment was repeated at least three times. 
 
2.4. RNA isolation and qRT-PCR 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). One μg of 
total RNA was reverse-transcribed using the Reverse-Transcription System (Qiagen, 
Hilden, Germany). Transcript levels of ALR and HPRT were quantified using 
real time PCR technology (Roche, Penzberg, Germany). Following primers were 
used (Metabion, Martinsried, Germany): ALR Fwd: 5'-gaagcgggacaccaagttta-3', ALR 
Rev: 5'-ttcagcacactcctcacagg-3'. HPRT Fwd: 5'-tgacactggcaaaacaatgca-3' and HPRT 
Rev: 5'-ggtccttttcaccagcaagct-3'. 
 
2.5. SDS-PAGE and immunoblotting 
Briefly, 30 μg total proteins per lane were separated by 12% SDS-PAGE (Biorad, 
Hercules, CA, USA), transferred onto PVDF membranes (Biorad, Hercules, CA, 
USA), incubated with specific antibodies and developed using enhanced 
chemiluminescence reagent (ThermoFisher Scientific, Darmstadt, Germany). 
Anti-ALR polyclonal antibody was prepared by Davids Biotechnology (Regensburg, 
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Germany), anti--actin antibody (#4970) was purchased from Cell Signaling 
(Danvers, MA). 
 
2.6. Electrophoretic mobility shift assay (EMSA) 
HepG2 cells were transfected with 500 ng Egr-1 expression plasmid. Nuclear 
extracts were prepared using NE-PER™ Nuclear and Cytoplasmic Extraction 
Reagents (ThermoFisher Scientific, Darmstadt, Germany) according to 
manufacturer’s description. Complementary synthetic biotin-labeled oligonucleotides 
corresponding to the Egr-1c-RE within ALR promoter were obtained from Metabion 
(Martinsried, Germany): Egr-1c-RE Fwd: 5'-cctgtccccgcccccgcccaggta-3'; Egr-1c-RE 
Rev: 5'-tacctgggcgggggcggggacagg-3'. Supershifting was performed using anti-Egr-1 
antibodies (Santa Cruz, CA, USA) after incubation with 2,5 µg nuclear extract for 
20 min at 4°C before adding the reaction. The biotin-labeled DNA was detected using 
enhanced chemiluminescence reagent (ThermoFisher Scientific, Darmstadt, 
Germany). Competition experiments were performed using a 200 fold excess of the 
same unlabeled binding site 20 min prior to electrophoresis using 6% DNA 
retardation gels (Biorad, Hercules, CA, USA). 
 
2.7. Statistical analysis 
All data are presented as mean plus/minus standard deviation of the mean. Data 
were compared between groups using the student t-test. p value of < 0,05 was 
considered significant. 
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3. Results 
3.1. Bile acids reduce the expression of ALR 
To analyze the role of bile acids in the regulation of ALR expression, HepG2 cells 
were incubated with increasing concentrations of deoxycholic acid (DCA). DCA is a 
secondary bile acid that is formed in the intestine and driven back to the liver by the 
portal vein where it activates several transduction pathways in hepatocytes to initiate 
apoptosis [29] and inflammatory response via Egr-1 activation [30]. mRNA and 
protein levels of ALR were evaluated by qRT-PCR and western blot, respectively. As 
shown in Fig. 1A, ALR transcription is significantly reduced after treatment with 
200 μM of DCA. Furthermore, long forms of ALR (21 and 23 kDa), were reduced 
upon treatment with DCA (Fig. 1B). In addition, transfected HepG2 cells transiently 
expressing sfALR (15 kDa) were treated with DCA to explore the effect of bile acids 
on the endogenously expressed sfALR. The expression of sfALR was reduced in 
HepG2-sfALR cells after treatment with DCA (Fig. 1C). These data suggest that bile 
acids treatment down-regulated ALR mRNA and protein expression in liver cells. The 
same experiments were performed in HepG2 cells over-expressing sodium 
taurocholate co-transporting polypeptide (NTCP, responsible for bile acid uptake into 
hepatocytes) (HepG2-NTCP) and showed similar results to HepG2 wild-type cells 
(data not shown). It is worth to mention that other bile acids like 
glycochenodeoxycholic acid (GCDCA) and glycocholic acid (GCA) also attenuated 
the protein expression of ALR (data not shown), which suggests that the molecular 
mechanism of ALR regulation by bile acids is not limited to a specific bile acid. 
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Fig. 1. Bile acids inhibit the expression of ALR. HepG2 cells were treated with 100 or 200 µM DCA for 
24 hours, followed by analyzing mRNA expression of ALR by qRT-PCR (A), and lfALR protein 
expression by western blot (B). (C) Western blot analysis demonstrated decreased sfALR protein 
expression (15 kDa) after transient transfection of sfALR expression plasmid into HepG2 cells and 
treatment with 100 or 200 µM of DCA for 24 hours. Densitometric analysis was performed by 
analyzing 3 different blots and a representative blot is illustrated (Three independent experiments, 
Mean±SD). 
 
3.2. ALR promoter harbors several bile acid-related response elements and its 
activity is reduced by bile acids 
Analysis of the human ALR 5’-flanking sequence (ALR GeneID 2671) revealed 
multiple response elements and binding site, a schematic illustration in Fig. 2A points 
out the response element for different transcription factors known to be regulated by 
bile acids and are therefore included in this study. ALR promoter study revealed two 
putative bile acid response elements (BARE I and BARE II) (AGGTCA and AGTTCA) 
respectively. Those BAREs [AG(T/G)TCA] were reported to be located at the 
promoter CYP7A1, and to regulate CYP7A1 expression [4, 5]. ALR promoter study 
also revealed three putative response elements for Egr-1 [GCCCCCG] at 
-149 to -140 (Egr-1a-RE), -114 to -107 (Egr-1b-RE) and +304 to +314 (Egr-1c-RE). 
Furthermore, a response element for HNF4α [AGGACTTTGGC] was identified at 
+421 to +432. Four truncated ALR promoter constructs were generated (Fig. 2A) to 
identify the response element responsible for ALR repression by bile acids. 
Construct 1 represents the full length of ALR promoter, construct 2 a truncated ALR 
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promoter lacking BARE II, construct 3 lacking Egr-1c-RE, FOXA2-RE, HNF4α-RE 
and BARE II and construct 4 that includes Egr-1a-RE and Egr-1b-RE. HepG2-NTCP 
cells were transfected with ALR promoter constructs and treated with DCA for 
24 hours. The luciferase activity assay revealed a significant reduction in ALR 
promoter activity upon DCA treatment in the full length promoter (construct 1) and 
construct 2 (lacking BARE II). On the other hand, the promoter activity remained 
unchanged in construct 3 and construct 4 (Fig. 2B). This suggests that ALR 
repression by DCA is mediated by a response element, such as FOXA2-RE, 
Egr-1c-RE as well as a HNF4α-RE. Moreover, BARE I and BARE II seem to be not 
involved in ALR repression by DCA. 
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Fig. 2. Bile acids reduce the activity of ALR promoter. (A) Schematic structure of the human ALR gene showing the location of three potential Egr-1 response 
elements (Egr-1-a,b,c-RE), two bile acid response elements (BARE), a potential HNF4 response element (HNF4-RE) and a verified FOXA2-RE. Construct 1 
(full length promoter) spans the region from -733 to +527 bp, construct 2 spans the region from -733 to +493 bp (lacking BARE II), construct 3 from -733 to 
+240 bp lacking BARE II, HNF4α, Egr-1c-RE and FOXA2-RE and construct 4 spans the region from -733 to -58 bp containing Egr-1a-RE and Egr-1b-RE. 
(B) Reporter gene assays using HepG2-NTCP transfected with full length and truncated ALR promoter constructs. Cells were treated with 100 µM DCA for 
24 hours and lysed to measure luciferase expression (five independent experiments, Mean±SD).  
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3.3. Egr-1-mediated activation of ALR expression is attenuated by bile acids 
Since ALR promoter harbors many putative Egr-1 response elements and bile acids 
were reported previously to activate Egr-1, HepG2 and Huh7 cells were transfected 
with Egr-1 to evaluate its impact on ALR promoter. As shown in Fig. 3A, the activity 
of the full length promoter (construct 1) was induced whereas the promoter lacking 
Egr-1c-RE (construct 3) remained unchanged after Egr-1 transfection. The induction 
in construct 1 activity was reversed by the addition of dominant negative Egr-1 
(dnEgr-1) which suggests that the Egr-1c-RE (+304 to +314) is responsible for 
Egr-1-mediated activity. This was confirmed by performing EMSA, oligonucleotides 
representing Egr-1c-RE were incubated with nuclear extracts of HepG2 
over-expressing Egr-1 and we analyzed the binding of Egr-1 to its response element.  
The protein-DNA complex in Fig. 3B is specific for Egr-1 because incubation with 
anti-Egr-1 antibody significantly reduced the complex formation (Fig. 3C). ALR 
protein expression was also induced by Egr-1 transfection (Fig. 3D). These data 
suggest that Egr-1 binds to (Egr-1c-RE) within ALR promoter and activates ALR 
expression. 
Since Egr-1 is activated under cholestatic conditions, we investigated the ability of 
bile acids to regulate ALR expression in the presence of Egr-1. Therefore, 
HepG2-NTCP cells were transfected with Egr-1 expression plasmid and the full 
length ALR promoter and treated with 100 µM DCA. We found that ALR promoter 
activity is reduced after DCA treatment despite the presence of Egr-1 (Fig. 3E). This 
was confirmed by performing EMSA assays demonstrating that Egr-1 binding to its 
response element is significantly reduced upon incubation with bile acids (Fig. 3F, 
lane 4 and Fig. 3G). Our data suggest that ALR induction by Egr-1 is attenuated by 
bile acids due to reduced Egr-1 binding to its response element. 
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Fig. 3. Induction of ALR expression by Egr-1 is attenuated by bile acids. (A) Reporter gene assays 
using HepG2 and Huh7 cells transfected with ALR-promoter constructs with/without Egr-1 expression 
plasmid or dnEgr-1 expression plasmid. Afterwards, cells were lysed to measure luciferase expression 
(three independent experiments, Mean±SD). (B) Labeled oligonucleotides representing the 
Egr-1C-RE (+304 to +314) were incubated in the absence or presence of nuclear extracts derived 
from HepG2 cells. For competition experiments a 200 fold excess of unlabeled Egr-1 consensus 
oligonucleotides were added (lane 2). Egr-1 specifically binds to Egr-1 binding site in ALR promoter 
(lane 3). Addition of anti-Egr-1 antibody reduced the formation of Egr-1-DNA complex (lanes 4 and 5). 
(C) Densitometric analysis of Egr-1 binding to its response element within ALR promoter after addition 
of anti-Egr-1 antibodies (three different experiments were analyzed). (D) Western blot analysis 
demonstrated an increased ALR protein expression (23, 21 and 15 kDa) upon transfection with Egr-1 
expression plasmid in HepG2 cells. (E) Reporter gene assays. HepG2-NTCP cells were transfected 
with full length ALR promoter construct with/without Egr-1 expression plasmid, treated with 
100 µM DCA for 24 hours and lysed to measure luciferase expression (three independent 
experiments, Mean±SD). (F) Labeled oligonucleotides representing the Egr-1c-RE (+304 to +314) 
were incubated in the absence or presence of nuclear extracts derived from HepG2 cells with/without 
treatment with 100 µM DCA for 15 minutes. For competition experiments a 200 fold excess of 
unlabeled Egr-1 consensus oligonucleotides were added (lane 2). Egr-1 specifically binds to Egr-1 
binding site within ALR promoter (lane 3). Treatment of the cells with DCA decreased the binding of 
Egr-1 to its response element (lane 4). (G) Densitometric analysis of Egr-1 binding to its response 
element within ALR promoter after treatment with 100 µM DCA for 24 hours (three different 
experiments were analyzed). 
 
3.4. Bile acids repress ALR activity through HNF4α1/SHP crosstalk 
We have shown so far that bile acids negatively regulate ALR expression (Fig. 1) 
independently from BARE I, BARE II (Fig. 2) and Egr-1 (Fig. 3). Therefore, we 
analyzed the role of HNF4α1 and SHP known to be regulated by bile acids by 
performing luciferase assays. The activity of the full length promoter is induced by 
co-transfection with HNF4α1 (Fig. 4A). Additionally, transfection with SHP reduces 
ALR promoter activity (Fig. 4A). However, transfection with HNF4α7 showed no 
increase in ALR expression (Fig. 4A). Interestingly, HNF4α1 increased ALR protein 
expression and adding SHP reversed this increase (Fig. 4B). Moreover, due to its 
known repression by bile acids through SHP, the effect of HNF4 on ALR expression 
was investigated. We found that bile acids reduce the protein expression of different 
isoforms of ALR (Fig. 4C) despite HNF4 transfection in both HepG2 and in sfALR 
transfected HepG2 cells. This suggests that HNF4α1 activates ALR expression and 
this activation is diminished by bile acid-activated SHP. 
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Fig. 4. Bile acid-regulated transcription factors (HNF41 and SHP) regulate ALR promoter activity and 
expression. (A) Reporter gene assays using HepG2 and Huh7 cells transfected with ALR-promoter 
construct 1 and HNF41, HNF47 or SHP expression plasmids. Three independent experiments, 
Mean±SD. p<0,05 * compared to transfection with pcDNA3.1, # compared to transfection with 
HNF41 expression plasmid. (B) ALR protein expression in HepG2 cells after transfection with 
mentioned expression plasmids. (C) Western blot analysis demonstrated decreased ALR protein 
expression after HNF41 transfection and treatment with 100 µM of DCA for 24 hours in both HepG2 
and sfALR transfected HepG2 cells (HepG2-sfALR). 
 
4. Discussion 
Over the last two decades, bile acids role as signaling molecules has gained growing 
attention. Bile acids regulate their synthesis by a negative feedback loop that 
involves FXR/SHP/HNF4α. Furthermore, bile acids accumulation causes liver injury 
by inducing apoptosis [12, 13], increasing mitochondrial instability [14] and activating 
the expression of chemotactic agents to attract inflammatory cells to the site of injury 
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[11]. Nevertheless, little is known about the regulation of pro-survival/anti-apoptotic 
factors by bile acids.  
ALR (Augmenter of liver regeneration) is a hepatoprotective factor that has been 
shown to be involved in several cellular processes like protein folding [31] and 
mitochondrial maintenance [32]. In addition, ALR is an anti-apoptotic factor that 
reduces death receptors expression and decreases ER-stress [21].Further, ALR 
expression has been shown to be activated by FOXA2 [25]. Additionally, oxidative 
stress was also shown to activate ALR expression via Nrf2 which suggested the anti-
oxidative properties of ALR [24]. Since bile acids accumulation causes oxidative 
stress and activation of Nrf2-target genes [15], we hypothesized that ALR expression 
might be regulated by bile acids. To assess the regulation of ALR by bile acids, we 
performed a promoter study including the first intron to include possible regulatory 
elements within introns which were proved to have an important role in the regulation 
of different target genes [33]. Interestingly, sequence analysis of ALR promoter 
revealed several putative “bile acid-regulated response elements”: BARE I, BARE II, 
Egr-1-a,b,c-RE and HNF4α-RE. qRT-PCR and western blot results showed that 
treatment with DCA represses the expression of ALR in its 3 isoforms. BAREs are 
known to be responsible for the negative feedback of CYP7A1 by bile acids [4, 5]. 
Nevertheless, deleting those response elements from the ALR promoter constructs 
did not affect the repression of ALR by DCA which suggests that BARE I and 
BARE II may not be involved in the regulation of ALR by DCA. Moreover, HNF4α1, 
but not HNF4α7, have shown an increase in ALR promoter activity as well as protein 
expression and this induction is reversed by SHP. SHP is an orphan nuclear factor 
that lacks a DNA binding domain [34] and is activated by bile acids’ nuclear receptor 
FXR [6]. Interestingly, SHP binds to other transcription factors and blocks their 
transcriptional activates [7]. Thus we could postulate that the negative regulation of 
ALR by bile acids is mediated by HNF4α1/SHP crosstalk.  
It was previously shown that liver regeneration is impaired in Egr-1 knock-out mice 
[35]. Furthermore, Egr-1 luciferase transgenic mice showed that Egr-1 is activated at 
the site of wound healing after partial hepatectomy [36]. interestingly, ALR was 
shown to have an augmenting effect on the process of hepatic healing after resection 
[37]. Moreover, ALR accumulates in vivo after partial hepatectomy and during liver 
regeneration [38, 39]. In our study we show that Egr-1 binds to its response element 
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within ALR promoter and increases its expression. Taken all together, this suggests 
Egr-1 as a novel inducer of ALR expression.  
It is worthwhile to mention that Egr-1 is also regulated by HNF4α/SHP [40]. Therefore 
we suggest that bile acids repress ALR expression by, at least, three possible 
mechanisms. First, the direct binding of bile acid-activated SHP to HNF4α1 blocks 
HNF4α1-activation of ALR. Second, SHP activation by bile acids represses Egr-1 
prolonged activation and therefore ALR expression is reduced. Third, the absence of 
ALR activating transcription factors like FOXA2 that translocates to the cytosol under 
cholestatic conditions [41] where it remains inactive.  
In the light of these data, we hypothesize that attenuated expression of anti-apoptotic 
and anti-oxidative ALR by bile acids contributes to the cholestatic liver injury, which 
suggests that boosting ALR expression under cholestatic conditions may be of 
benefit for hepatocytes by promoting pro-survival and anti-apoptotic effects. 
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Abstract 
During cholestatic liver diseases, bile acids accumulate and therefore cause liver 
injury. The mechanism of this injury includes signaling pathways that initiate oxidative 
stress, ER-stress and apoptosis in hepatocytes and cholangiocytes. Interestingly, 
innate immune cells in the liver have been shown to contribute to liver injury during 
cholestasis. As an outcome of hepatocyte injury, T helper cells are activated and 
release IL17. IL17 binds to its receptor and particularly activates Kupffer cells. When 
activated, Kupffer cells increase the expression and release of IL6, IL1 and TNF 
that were shown to influence cholestatic liver injury e.g. by altering bile acid synthesis 
and transport. Augmenter of liver regeneration (ALR) is a hepatotrophic growth factor 
that was found to have anti-oxidative and anti-apoptotic properties. Interestingly, 
application of recombinant ALR protein in bile duct ligated-rats has been 
demonstrated to attenuate liver injury. Moreover, ALR is positively regulated by IL6 
via increased recruitment of FOXA2 (Forkhead Box A2, an inducer of ALR) to its 
binding site within ALR promoter. However, little is known about ALR regulation by 
Kupffer cell-released IL1. Therefore, we aimed to investigate the expression of ALR 
by IL1 and to elucidate the molecular mechanism of this regulation. We found that 
ALR promoter activity as well as mRNA and protein expression are reduced upon 
treatment with IL1. Furthermore, expression of SP1 (Specificity Protein 1), an 
inducer of ALR, was reduced upon IL1 treatment. Moreover, Egr-1 (early growth 
response protein-1) was induced by IL1 but could not activate the expression of 
ALR which could be attributed to reduced Egr-1 binding to ALR promoter upon 
treatment with IL1. In conclusion, this study offers evidence about the regulation of 
anti-apoptotic and anti-oxidative ALR by IL1 and suggests a further role of Kupffer 
cells in cholstatic liver injury. 
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1. Introduction 
Cholestatic liver diseases occur when excretion of bile acids is impaired due to either 
a direct inhibition of bile flow or genetic defects impairing bile acid transporters [1, 2]. 
Whatever the cause, hepatic bile acids accumulation causes liver injury by inducing 
apoptosis [3, 4], manipulating the mitochondrial membrane stability by oxidative 
stress and ROS (reactive oxygen species) production [5] as well as attracting 
inflammatory cells [6]. Furthermore, cholestatic liver injury may lead to liver fibrosis, 
cirrhosis and possibly to liver failure if it is left untreated [7]. The inflammatory 
response during cholestasis is initiated by hepatocytes which release several 
cytokines upon injury [8]. It was previously reported that exposure of cultured mouse 
hepatocytes to bile acids leads to a pathologically relevant increase in the expression 
of ICAM1 (Intercellular Adhesion Molecule-1), MIP2 (Macrophage Inflammatory 
Protein-2) and MCP1 (Monocyte Chemoattractant Protein 1) [6, 9]. Interestingly, this 
induction was attributed to increased Egr-1 (early growth response protein-1) 
expression [6, 10]. This was further confirmed in isolated human hepatocytes that 
showed increased release of cytokines into culture medium upon treatment with bile 
acids [8]. Furthermore, the hepatocyte-released cytokines enhanced neutrophils 
chemotaxis to the site of injury which initiate the inflammatory response [8]. 
Moreover, cholestatic liver injury is affected by hepatic macrophages which include 
liver resident Kupffer cells and bone marrow-derived monocytes/macrophages [11, 
12]. Recent studies have shown that activation of Kupffer cells by IL17 (released 
from T helper cells and neutrophils during cholestasis) [13, 14] leads to the induction 
of TNF and IL1 (pro-inflammatory cytokines) [15]. Moreover, exposure of 
macrophages to bile acids activates TGR5 (G-protein coupled bile acid receptor) and 
reduces pro-inflammatory cytokines while maintaining anti-inflammatory cytokines 
(IL4, IL10 and IL13) expression thus promoting the development of an anti-
inflammatory macrophage phenotype [16]. In addition, it was shown that IL1 and 
TNF are involved in the downregulation of hepatic organic anion transporters in 
cholestasis like NTCP (Na+-Taurocholate Co-transporting Polypeptide) and BSEP 
(Bile Salt Export Pump) [17, 18]. Therefore, these findings indicate that Kupffer cells 
may contribute to cholestatic liver injury. 
Augmenter of Liver Regeneration (ALR), a hepatotrophic growth factor [19], is 
constitutively expressed and stored in the hepatic parenchymal cells [20-22]. ALR 
was previously shown to attenuate free fatty acid induced-apoptosis [23]. Further, 
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ALR acts as an anti-apoptotic/ cell survival factor in hepatoma cells after oxidative 
stress injuries [24, 25]. Moreover, ALR was shown to modulate the reaction of 
hepatocytes to IL6 treatment by altering the activation of STAT3 (signal transducer 
and activator of transcription 3) [26]. It was previously demonstrated that exposure of 
hepatic cells to oxidative stress activates Nrf2 (Nuclear factor erythroid 2–related 
factor 2) which in turn activates ALR expression [27]. In addition, FOXA2 
(Forkhead Box A2) binds to ALR promoter and increases its expression and this 
binding is enhanced by IL6 [28]. However, the regulation of the heptoprotective 
factor, ALR, by cholestasis-induced cytokine IL1 has not been investigated, 
therefore we aimed to analyze the regulation of ALR expression by IL1 and to 
elucidate which transcription factors are involved in this regulation. 
 
2. Materials and methods 
2.1. Cell culture 
The human hepatoma cell line HepG2 was obtained from American Type Culture 
Collection (HB-8065, ATCC, Manassas, VA) and grown at 37°C, 5% CO2 in DMEM 
(BioWhittaker, Verviers, Belgium) supplemented with penicillin (100 units/ml), 
streptomycin (10 μg/ml) and 10% fetal calf serum (Biochrom, Berlin, Germany). IL1 
(50 ng/ml) (PeproTech GmbH, Hamburg, Germany) was added after 24 hours 
starvation for indicated times. 
 
2.2. Transient transfection and reporter gene assays 
HepG2 cells were cultured at the density of 5x104 cell/cm2, cells were then 
transfected using Lipofectamine® 3000 (ThermoFisher Scientific, Darmstadt, 
Germany) with 200 ng of human ALR promoter construct (-733/+527) (reported 
in [28]) and 200 ng of either pcDNA3.1or pcDNA3.1-Egr-1 expression plasmid 
(a generous gift from Xiaojia Chen, China). After 24 hours, IL1 was added 
(50 ng/ml) for indicated times. Dual luciferase assays were carried out 24 hours after 
transfection using dual luciferase reporter assay system (Promega, Mannheim, 
Germany). pRL-TK Renilla-vector was co-transfected to determine transfection 
efficiency and the promoterless vector pGL2-basic served as negative control. Each 
experiment was repeated at least three times.  
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2.3. RNA isolation and qRT-PCR 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). One μg of 
total RNA was reverse-transcribed using the Reverse-Transcription System (Qiagen, 
Hilden, Germany). Transcript levels of ALR, SP1, Egr-1 and HPRT were quantified 
using real-time PCR technology (Roche, Penzberg, Germany). PCR reaction 
products were verified by sequence analysis and each quantitative PCR was 
performed in triplicates. Table (I) includes the used primers for qRT-PCR. 
 
2.4. SDS-PAGE and immunoblotting 
Total proteins were isolated, prepared and subjected to western blot analysis. Briefly, 
30 μg per lane were separated by 12% SDS-PAGE (Biorad, Hercules, CA, USA) and 
proteins were transferred onto PVDF membranes (Biorad, Hercules, CA, USA), 
incubated with specific antibodies and developed using enhanced 
chemiluminescence reagent (ThermoFisher Scientific, Darmstadt, Germany). 
Anti-ALR polyclonal antibody was prepared against 15 kDa ALR (short form ALR) 
prepared by Davids Biotechnology (Regensburg, Germany), anti--actin antibody 
was purchased from Cell signaling (Danvers, MA) and anti-Egr1 purchased from 
Santa Cruz (CA, USA). 
 
Table (I): Primers used in qRT-PCR expreiments 
ALR, sense 5'-gaagcgggacaccaagttta-3' 
ALR, antisense 5'-ttcagcacactcctcacagg-3' 
SP1, sense 5'-ttgaaaaaggagttggtggc-3' 
SP1, antisense 5'-tgctggttctgtaagttggg-3' 
Egr-1, sense 5'-tactcctctgttccccctgctt-3' 
Egr-1, antisense 5'-gaaaaggttgctgtcatgtccg-3' 
HPRT, sense 5'-tgacactggcaaaacaatgca-3' 
HPRT, antisense 5'-ggtccttttcaccagcaagct-3' 
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2.5. Electrophoretic mobility shift assay (EMSA) 
HepG2 cells were transfected with 500 ng of Egr-1 expression plasmid and nuclear 
extracts were prepared using NE-PER™ Nuclear and Cytoplasmic Extraction 
Reagents (ThermoFisher Scientific, Darmstadt, Germany) according to the 
manufacturer’s description. Complementary synthetic biotin-labeled oligonucleotides 
corresponding to the Egr-1 binding site (+304/+314) within ALR promoter were 
obtained from Metabion (Martinsried, Germany): Egr-1-RE Fwd: 
5'-cctgtccccgcccccgcccaggta-3'; Egr-1-RE Rev: 5'-tacctgggcgggggcggggacagg-3', for 
mutated potential overlapping SP1 binding site following oligonucleotides were used 
(mutated nucleotides are underlined): Egr-1-ΔSp1-Fwd: 
5'-cctgtccttgcccccgcccaggta-3' and 
Egr-1-ΔSp1-Rev:5'-tacctgggcgggggcaaggacagg-3'. The biotin-labeled DNA was then 
detected using enhanced chemiluminescence reagent (ThermoFisher Scientific, 
Darmstadt, Germany). Competition experiments were performed using a 200 fold 
excess of the same unlabeled binding site 20 min prior to electrophoresis using 
6% DNA retardation gels (Biorad, Hercules, CA, USA) at room temperature. 
 
2.6. Statistical analysis 
All data are presented as mean plus/minus standard deviation of the mean. Data 
were compared between groups using the student t-test. p value of < 0,05 was 
considered significant. 
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3. Results 
3.1. IL1 treatment reduces ALR promoter activity and expression 
To analyze the activity of ALR promoter upon IL1 treatment, HepG2 cells were 
transfected with an ALR promoter construct (-733/+523) and then treated with 
50 ng/ml IL1 for 2, 4, 8, 16 and 24 hours. As shown in Fig. 1A. ALR promoter 
activity is significantly reduced after 4 hours of IL1 treatment. Furthermore, mRNA 
expression of ALR was reduced upon treatment with IL1 (Fig. 1B). In addition, 
mRNA levels of SP1 (specificity protein 1, an inducer of ALR expression [29]) were 
accordingly reduced upon IL1 treatment (Fig. 1B). This was further confirmed by 
performing western blot to investigate ALR protein expression after IL1 treatment. 
ALR expression was reduced after 16 and 24 hours of IL1 treatment (Fig.1C). 
These results suggest that IL1 reduces the expression of ALR and this reduction 
might be mediated, at least partially, by the reduced expression of SP1. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Effect of IL1 on ALR promoter activity and expression. (A) HepG2 cells were transfected with 
ALR promoter construct (-733 to +527 bp), starved for 24 hours and then treated with 50 ng/ml IL1 
for indicated time points, cells were then lysed to measure luciferase expression (three independent 
experiments, Mean±SD). (B) HepG2 cells were starved for 24 hours and then incubated with 50 ng/ml 
of IL1 for indicated times. mRNA levels of ALR and SP1 were analyzed and normalized to HPRT. (C) 
Western blot analysis using specific anti-ALR antibodies demonstrated decreased ALR protein 
expression in HepG2 cells upon treatment with 50 ng/ml IL1 for 16 or 24 hours (-actin served as 
loading control). 
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3.2. IL1 reduces the Egr-1-mediated ALR induction 
Egr-1, a zinc finger transcription factor, induces ALR expression by binding to its 
response element within ALR promoter [30]. On the other hand IL1 was shown to 
increase the expression of Egr-1 [31, 32]. Therefore the effect of Egr-1 on ALR 
expression under conditions of high IL1 concentrations was analyzed. ALR 
promoter construct was co-transfected with an Egr-1-expression plasmid and 
promoter activity was analyzed upon treatment with 50ng/ml of IL1 for 2, 4, 8, 16 
and 24 hours. As shown in Fig. 2A, Egr-1 activates ALR promoter activity. This 
activity is then significantly reduced after IL1 application for 4, 8 and 16 hours. 
Moreover, the mRNA expression of Egr-1 (Fig. 2B) is increased 16 and 24 hours 
after IL1 treatment. Egr-1 protein expression was analyzed and showed an increase 
24 hours after IL1 application (Fig. 2C). This was further confirmed by performing 
EMSA to analyze Egr-1 binding to its response element within ALR promoter after 
IL1 treatment. We found that Egr-1 binds to its response element within ALR 
promoter and this binding is reduced after the application of IL1 (Fig. 2D). 
Furthermore, mutating the potential overlapping SP1 response element next to Egr-1 
response element [31, 33] increases the DNA-protein binding of Egr-1. The binding is 
nevertheless reduced upon IL1 treatment (Fig. 2D). Based on these data, we 
propose that ALR suppression by IL1 might be attributed to reduced Egr-1 binding 
to its binding site within ALR promoter (+304/+314). However, this reduced binding of 
Egr-1 to ALR promoter seems to be SP1 independent.  
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Fig. 2. Effect of IL1 on the expression of Egr-1. HepG2 cells were starved for 24 hours and then 
incubated with 50 g/ml of IL1 for indicated times (A) ALR promoter activity was measured after 
transfection with Egr-1 expression plasmid and then addition of IL1 for indicated time points (three 
independent experiments, Mean±SD). (B) mRNA levels and (C) protein expression of Egr-1 upon 
treatment with IL1 with the corresponding densitometric analysis. (D) Schematic illustration of the 
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overlapping binding sites of Egr-1 and SP1 within ALR promoter (+300, +317) and the mutations 
(CT) generated in the potential SP1 binding site are underlined. (E) Labeled oligonucleotides 
representing Egr-1 binding site (+304/+314) with wild type SP1 binding site (WT) or mutated SP1 
binding site (SP1). Oligonucleotides were incubated in the absence or presence of nuclear extracts 
derived from HepG2 cells with or without treatment with 50 ng/ml IL1 for 15 minutes. For competition 
experiments a 200 fold molar excess of unlabeled Egr-1 consensus oligonucleotides were added (lane 
2). Egr-1 specifically binds to Egr-1 binding site within ALR promoter (lane 3). Treatment of the cells 
with IL1 decreased the binding of Egr-1 to its response element (lane 4). Lane 5 and 6 represent the 
SP1 oligonucleotides. Increased Egr-1 binding to DNA upon SP1 mutation (lane 5), this binding is 
nevertheless reduced after IL1 addition (lane 6). 
 
4. Discussion 
Cholestasis is a pathological syndrome caused by impaired or disrupted bile flow 
from the liver [34]. As an outcome, bile acids (main component of the bile) 
accumulate and cause apoptosis [3, 4], oxidative stress [5] and attract inflammatory 
cells [6]. Upon exposure to toxic bile acids, hepatocytes activate the expression of 
chemokines like ICAM1 and MIP2 that attract neutrophils [6]. Furthermore, IL17, 
released from T helper cells, activates intrahepatic macrophages (Kupffer cells) 
[13, 14] which in turn release several pro-inflammatory cytokines like IL1 and TNF 
[15]. Interestingly, accumulating evidence have emphasized the role of IL1 and 
TNF in modulating cholestatic injury, like altering expression of bile acid 
transporters [17, 18] and inhibiting the expression of bile acid synthesis enzymes 
[35, 36]. Furthermore, IL1 receptor knockout mice has demonstrated that these 
mice show insusceptibility against LPS challenge after BDL, secreting fewer 
cytokines and showing lower mortality compared with wild-type mice [37]. Another 
study in TNF-α knockout mice showed improved survival rate and attenuated 
BDL-induced liver damage and fibrosis [38]. These studies indicate that Kupffer cells 
and their cytokines are associated with mortality in cholestatic liver injury [39]. 
Nevertheless, the molecular mechanism of cytokine-induced injury is not fully clear. 
Augmenter of liver regeneration (ALR) is an anti-apoptotic and an ER-stress reducing 
factor [23]. Furthermore, ALR is activated by Nrf2 upon exposure to oxidative stress 
and is therefore considered anti-oxidative [27]. Additionally, application of 
recombinant ALR to bile duct-ligated rats was demonstrated to reduce serum 
transaminases and preserve mitochondrial DNA [40]. Moreover, it has been shown 
that endogenous short form ALR (15 kDa) increases that activation of STAT3 (signal 
transducer and activator of transcription 3) [26] and thereby alters the reaction of 
hepatocytes to IL6 signaling. Interestingly, it was previously demonstrated that 
STAT3 is a negative regulator of the bile acid synthesis and protects from bile acid-
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induced apoptosis [41]. Additionally, STAT3 activation reduces the expression of 
death receptor 5 (DR5) [42]. Therefore, enhancing the expression of ALR in 
hepatocytes might protect hepatocytes against the toxicity of bile acids during 
cholestasis. 
It has been previously reported that ALR expression is enhanced by IL6 [28]. 
Furthermore, TNF was demonstrated to increase the release of ALR in an in vitro 
model [43] which could be attributed to increased nuclear localization of ALR’s 
inducer FOXA2 [44] or induction of Egr-1 [45], another inducer of ALR expression 
[30]. Nevertheless, little is known about the regulation of ALR expression by Kupffer 
cell-released IL1. We assessed the regulation of ALR by IL1 by luciferase assays, 
qRT-PCR and western blot techniques and found that ALR expression and promoter 
activity are reduced by IL1. Interestingly, expression of SP1 (an activator of ALR 
expression [29]) was reduced by IL1. This is in line with previous reports showing 
that SP1 expression [46] as well as promoter occupancy [31] in chondrocytes are 
decreased by IL1. Therefore, we hypothesis that reduced SP1 expression might be, 
in part, responsible for reduced ALR expression. Furthermore, Egr-1 expression, an 
inducer for ALR [30], is induced by IL1 [31, 32]. We analyzed the ability of Egr-1 to 
regulate ALR promoter activity in the presence of IL1 and found that Egr-1-induced 
ALR promoter activity is reversed by IL1 due to reduced Egr-1 binding to ALR 
promoter. It is worth to mention that the negative regulation of ALR by IL1 could be 
due to induced AP1 expression [47]. AP1 was previously reported to bind to its 
binding site (-375/-369) within ALR promoter and repress its activity [48]. Moreover, 
the repressed expression of HNF4 by IL1 [49] may contribute to ALR repression 
by the absence of ALR activator, HNF4 [30]. In conclusion, the decreased 
expression of anti-apoptotic and anti-oxidative ALR by IL1 might be considered a 
further contribution of Kupffer cells to cholestatic liver injury and suggests that 
boosting the expression of ALR during cholestasis could be of clinical interest due to 
its heptoprotective properties in reducing bile acids synthesis and reducing bile 
acid-induced apoptosis. 
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Abstract 
Cholestasis represents pathophysiologic syndromes defined as an impaired bile flow 
from the liver. As an outcome, bile acids accumulate and promote hepatocytes injury 
followed by liver cirrhosis and liver failure. Bile acids induce apoptosis, ER stress and 
mitochondrial membrane instability. In this study we aimed to investigate the role of 
cytosolic short form of ALR (Augmenter of Liver Regeneration) in the synthesis of bile 
acids and bile acid-induced apoptosis. Human hepatoma cells over-expressing the 
short form of ALR (sfALR, 15 kDa) were incubated with glycochenodeoxycholic acid 
(GCDCA), and then primary bile acids’ production and apoptosis were analyzed. 
High levels of cytosolic sfALR reduced CYP7A1 mRNA expression and activity, the 
rate-limiting enzyme in the classic pathway of bile acid synthesis. This reduction was 
attributed to the STAT3 (signal transducer and activator of transcription 3) activation 
and reduction of HNF4α (Hepatocyte nuclear factor 4). Furthermore, apoptosis 
induction by GCDCA and TRAIL was reduced in cells over-expressing sfALR which 
was attributed to reduced expression of death receptor 5 (DR5). We found decreased 
hepatic mRNA levels of ALR and FOXA2 (Forkhead Box A2), an inducer of ALR 
expression, in human cholestatic liver samples which might explain the increased 
accumulation of bile acids and bile acid-induced apoptosis in cholestasis patients. 
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1. Introduction 
Gallstones, local tumors and the genetic deficiencies in bile acids exporters amongst 
other different etiologies are common causes of cholestatic liver diseases [1, 2]. By 
definition, cholestasis represents pathophysiologic syndromes defined as an 
impaired bile flow from the liver. As an outcome, bile acids accumulate and promote 
hepatocytes injury followed by the development of liver cirrhosis and liver failure [3]. 
Considered to be both lipids emulsifiers and signaling molecules, bile acids are 
preserved in normal biological levels by a tight regulation feedback-loop. The 
de novo synthesis of bile acids proceeds via two different pathways: the classical 
pathway and the alternative pathway. First, the classical pathway accounts for 90% 
of the total bile acid pool, thereby the regulation of its rate-limiting enzyme 
cytochrome P450 7A1 (CYP7A1) has received great attention. CYP7A1 initiates the 
catabolism of cholesterol into primary bile acids (cholic acid: CA and 
chenodeoxycholic acid: CDCA) [4, 5]. Second, the alternative pathway of bile acid 
synthesis (also known as the acidic pathway) accounts for 10% of the total bile acid 
pool and is rate-limited by CYP27A1 (mitochondrial 27-hydroxylase). The main 
product of this pathway is CDCA [6, 7]. The promoter of CYP7A1 gene harbors 
several response elements to which different transcription factors can bind and 
further activate or repress its activity. Hepatocyte nuclear factor 4 (HNF4) and 
Liver-related homolog-1 (LRH-1) bind to the “bile acid response element II” (BARE II) 
within CYP7A1 promoter and activate its transcription. Upon accumulation, bile acids 
bind to their nuclear receptor, farnesoid x receptor (FXR) [8], which in turn activates 
small heterodimer partner (SHP), SHP then blocks HNF4 and LRH-1-mediated 
activation of CYP7A1 [9]. MicroRNAs could also regulate CYP7A1 indirectly by 
controlling transcription factors known to regulate its expression. It was reported that 
STAT3 (signal transducer and activator of transcription 3) phosphorylation activates 
miRNA24 and miRNA629 leading to downregulation of HNF4α [10]. 
Under cholestatic conditions, hepatocytes are exposed to elevated concentrations of 
bile acids, which alters gene expression in different pathways. Moreover, bile acids 
were proved to induce apoptosis by increasing the expression of TRAIL-receptor 2, 
also known as death receptor 5 (DR5), through activation of JNK pathway, thereby 
sensitizing hepatocytes to TRAIL-mediated apoptosis [11, 12]. Bile acid-induced 
apoptosis can also be mediated by Fas receptor (FasR or CD95) [13]. Upon 
micromolar exposure of glycochenodeoxycholate (GCDCA), hepatocytes induce 
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FasR aggregation on the plasma membrane [13, 14] which promotes its 
oligomerization and initiates a death-signaling pathway [15]. 
Augmenter of liver regeneration (ALR), a hepatotrophic growth factor [16], is 
constitutively expressed and stored in the hepatic parenchymal cells [17-19]. 
Subcellular fractionation of mitochondria and cytosol of primary human hepatocytes 
(PHH) revealed the expression of mainly 3 isoforms of ALR, a 21 and a 23 kDa 
isoform, both located in mitochondria and cytosol and a 15 kDa isoform (the short 
form, hereafter sfALR) detected solely in the cytosol of hepatocytes [20]. sfALR 
reduces ER-stress, lipoapoptosis and cellular steatosis following treatment with free 
fatty acids [20]. In addition, we have previously shown the ALR is induced by Nrf2 
(nuclear factor erythroid-2 like factor 2) [21] which is known to regulate anti-oxidative 
genes like GCLC (glutamate cysteine ligase catalytic subunit) and NQO1 (NAD(P)H 
quinone oxidoreductase 1) [22, 23]. Interestingly, high levels of cytosolic sfALR 
induce the reaction of hepatocytes to IL6 treatment by increasing the tyrosin 
phosphorylation of STAT3, without affecting STAT3 expression, leading to altered 
gene expression in liver cells [24]. 
The aim of the current study was to analyze the expression of ALR under cholestatic 
conditions and to elucidate a potential protective effect of sfALR in cholestatic liver 
injuries, in regards to bile acid synthesis and accumulation as well as bile 
acid-induced apoptosis.  
 
2. Materials and methods 
2.1. Human liver samples and primary human hepatocytes 
Experimental procedures were performed according to the guidelines of the 
charitable state controlled foundation HTCR (Human Tissue and Cell Research, 
Regensburg, Germany), with the written informed patient's consent. The study and 
the consent form were approved by the local ethical committee of the University of 
Regensburg (ethics statement 12-101-0048, University of Regensburg, Germany). All 
experiments involving human tissues and cells have been carried out in accordance 
to The Code of Ethics of the World Medical Association (Declaration of Helsinki).  
Human liver tissues from 58 patients were collected, including 45 liver samples for 
the “cholestasis” group and 13 samples of “normal” liver tissue. Cholestatic livers 
(n=13 obstructive extrahepatic cholestasis, n=3 obstructive intrahepatic cholestasis, 
n=24 non-obstructive cholestasis) were chosen based on histopathological 
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examination of liver sections with positivity for proliferating bile ducts. Normal liver 
samples were collected from patients with liver metastasis due to colorectal 
carcinoma. Liver sections collected from those patients showed no signs of 
histopathological cholestasis (for clinico-pathological characteristics of the cohort see 
Table 1). Primary human hepatocytes (PHH) were isolated from normal (n=3) and 
cholestatic (n=8) liver tissues and analyzed by qRT-PCR [21, 25]. 
  
Table (I): Clinico-pathological parameters of patients in the study cohort (serum 
parameters: Bilirubin, Alkaline phosphatase (ALP), Alanine transaminase (ALT), 
Gamma-glutamyltransferase (GGT). Data are showed as mean and range of values) 
and p values between normal and cholestatic patients. 
Parameter Normal liver 
(n=13) 
Cholestatic liver 
(n=45) 
P value  
Gender 
(female / male) 
(7/6) (28/17) 
- 
Age [years] 
(mean/range) 
55,92 (30-66) 52,62 (19-78) 
0,502 
Bilirubin [mg/dl] 0,60 (0,30-0,90) 9,06 (1,00-34,43) <0,001a 
ALP [U/L] 83,20 (46-137) 222,60 (23-540) <0,001 
ALT [U/L] 21,98 (8-33) 169,54 (5-1959) <0,001 
GGT [U/L] n.d. 364,88 (15-1558) - 
 
a Boldfaces indicate significant differences. 
 
2.2. Cell culture and treatments 
The human hepatoma cell line HepG2 was obtained from American Type Culture 
Collection (HB-8065, ATCC, Manassas, VA) and grown at 37°C, 5% CO2 in DMEM 
(BioWhittaker, Verviers, Belgium) supplemented with penicillin (100 units/ml), 
streptomycin (10 μg/ml) and 10% fetal calf serum (Biochrom, Berlin, Germany). Cells 
were seeded at a density of 5x104 cells/cm2 and treated for 24 hours with 100 µM of 
each bile acid (glycochenodeoxycholic acid (GCDCA), taurochenodeoxycholic acid 
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(TCDCA), taurolithocholic acid (TLCA) and glycocholic acid (GCA) all obtained from 
Sigma-Aldrich, St. Louis, MO). For caspase 3/7 assays, 100 µM of AG490 (Merck, 
Darmstadt, Germany) and 25 ng/ml TRAIL (Abcam, Cambridge, UK) were applied to 
cells for 24 and 6 hours respectively. Supernatants were collected and mRNA and 
protein samples were isolated and appropriately stored for upcoming analyses. 
Stable transfection has been previously reported [26]. Transfected HepG2 cells with 
sfALR are referred to as HepG2-sfALR cells. 
 
2.3. RNA isolation, reverse transcription and qRT-PCR 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). One μg of 
total RNA was reverse-transcribed using the Reverse Transcription System (Qiagen, 
Hilden, Germany). Transcript levels of CYP7A1, HNF4α, HPRT, ALR, FOXA2 and 
YWHAZ were quantified using real-time PCR technology (Roche, Penzberg, 
Germany). Amplicons were verified by sequence analysis and each quantitative PCR 
was performed in duplicates for 3 sets of RNA preparations. The following primers 
were used: for CYP7A1, sense 5'-gaatgctggtcaaaaagtc-3' and anti-sense 
5'-tgaaatcctccttagctgt-3', for HNF4α, sense 5'-tgtcccgacagatcacctc-3' and anti-sense 
5'-cactcaacgagaaccagcag-3', for HPRT, sense 5'-tgacactggcaaaacaatgca-3' and anti-
sense 5'-ggtccttttcaccagcaagct-3', for ALR, sense 5'-gaagcgggacaccaagttta-3' and 
anti-sense 5’-ttcagcacactcctcacagg-3’, for YWHAZ, sense 5'-gcaattactgagagacaactt 
gaca-3' and anti-sense 5'-tggaaggccggttaatttt-3' and for FOXA2 sense 5’-ccgttctccatc 
aacaacct-3’ and anti-sense 5’-ggggtagtgcatcacctgtt-3’. 
 
2.4. Measurement of primary bile acids in supernatant (effeciency of bile acid 
synthesis enzymes) 
HepG2 and HepG2-sfALR cells were cultured at a density of 5x104 cells/cm2, after 
24 hours, 800 µL of serum free medium was applied to the cells and 4 hours later the 
supernatant was collected to determine the levels of primary bile acids (free and 
conjugated) by LC-MS/MS. The measured concentrations were later normalized to 
protein concentration in each sample. This method of measurement has been 
previously reported [27] and recently updated [28]. 
 
2.5. SDS-PAGE and immunoblotting 
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Total protein homogenates (30 μg per lane) were separated by 12% SDS-PAGE 
(Biorad, Hercules, CA, USA) under reducing conditions using 100 mM DTT. Proteins 
were transferred onto PVDF membranes (Biorad, Hercules, CA, USA), incubated 
with specific antibodies and developed with ECL reactions (Pierce, Rockford, IL, 
USA). Nuclear fractions were prepared using NE-PERTM Nuclear and Cytoplasmic 
Extraction Reagents (ThermoFisher Scientific, Darmstadt, Germany). Following 
antibodies were used: anti-HNF4α (#3113), anti-death receptor 4 (#42533), anti-
FasR (C1812,), anti-STAT3 (#9139), anti-ß-actin (#4970), anti-GAPDH (#5174), anti 
pNFкB (p-p65) (#8242) and anti-NFкB (p65) (#3033) all obtained from Cell Signaling 
(Danvers, MA). Anti-HDAC1 (#05-100) purchased from Merck (Darmstadt, Germany), 
anti-death receptor 5 (DR5) (#ab8416) and anti-pSTAT3 (Tyr705) (#ab76315) were 
obtained from Abcam (Cambridge, UK). Secondary goat HPR-conjugated antibodies 
(anti-rabbit # P0448 and anti-mouse #P0447) were obtained from Dako (Hamburg, 
Germany). 
 
2.6. Caspase 3/7 activity 
Following treatments, cells were subjected to caspase 3/7 activity measurement with 
Caspase-Glo 3/7 Assay (Promega, Madison, USA) according to the manufacturer's 
instructions. 
 
2.7. Statistical analysis 
All data are presented as mean plus/minus standard deviation of the mean. Data 
were compared between groups using Mann-Whitney test. p value of <0,05 was 
considered significant. Correlation coefficients were calculated using Spearman’s 
correlation test. 
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3. Results 
3.1. Over-expressed cytosolic short form ALR (sfALR) diminishes the 
expression of CYP7A1 and bile acid synthesis 
Initially, to investigate the potential effect of over-expressed cytosolic sfALR on the 
de novo synthesis of bile acids we used HepG2 (expressing the long forms of ALR, 
23 and 21 kDa) and HepG2-sfALR cells (additionally over-expressing short form of 
ALR, 15 kDa) (Fig. 1A). mRNA expression of CYP7A1 was analyzed by qRT-PCR in 
HepG2 and sfALR-expressing HepG2 cells with or without incubation with different 
bile acids. Since TCDCA, GCDCA, GCA (primary bile acids) and TLCA (secondary 
bile acid) were shown to be elevated in cholestatic patients [29] we chose those bile 
acids to compare their potential effect in the sfALR-mediated regulation of CYP7A1. 
HepG2-sfALR cells showed a significantly less CYP7A1 expression (60% reduction) 
compared with wild type HepG2 cells without treatment (Fig. 1B). Interestingly, 
treatment with TCDCA and TLCA almost abolished CYP7A1 mRNA expression in 
HepG2-sfALR cells when compared with similarly treated HepG2 cells (Fig. 1B). In 
addition, the mRNA expression of CYP27A1, the rate-limiting enzyme for the 
alternative pathway of bile acids synthesis, was analyzed and showed no significant 
change in HepG2-sfALR cells (data not shown). Moreover, CYP8B1 (involved in 
subsequent steps after CYP7A1 in the classical pathway of CA synthesis) was 
analyzed and showed no significant change in HepG2-sfALR cells (data not shown). 
To confirm the mRNA data, we used LC-MS/MS to assess the efficiency of bile acid 
synthesis enzyme by determining the levels of taurine- and glycine-conjugated 
primary bile acids (CA and CDCA), products of the classic pathway of bile acid 
synthesis. HepG2-sfALR cells, compared to HepG2 cells, showed a 30% reduction in 
total primary bile acid pool (free and conjugated) (Fig. 1C). This reduction in primary 
bile acids in HepG2-sfALR was attributed mainly to a reduction in CDCA 
concentration and partially to reduction in TCA concentration (Fig. 1D).  
These data indicate that over-expressed cytosolic sfALR reduces the de novo 
synthesis of bile acids by the classical pathway through modulating the expression of 
its rate limiting enzyme CYP7A1 without affecting the alternative pathway of bile acid 
synthesis. On the other hand, the proportions of free and conjugated bile acids were 
not altered in HepG2-sfALR cells which suggests that sfALR reduces the overall pool 
of primary bile acids without affecting its composition (data not shown). 
. 
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Fig. 1. Over-expressed cytosolic sfALR diminishes the expression and the activity of CYP7A1. (A) 
HepG2 and HepG2 over-expressing sfALR (HepG2-sfALR) cells were analyzed for ALR mRNA levels 
by qRT-PCR with HPRT as housekeeping gene and normalized to HepG2 cells (three independent 
experiments, mean ± SD). Total protein was isolated and isoforms of ALR and GAPDH were analyzed 
by western blot techniques (GAPDH served as a loading control). (B) HepG2 and HepG2 expressing 
sfALR (HepG2-sfALR) cells were incubated for 24 hours with or without 100 µM of each bile acid. 
mRNA levels of CYP7A1 were analyzed by qRT-PCR with HPRT as housekeeping gene and 
normalized to untreated HepG2. The supernatants from untreated HepG2 and HepG2-sfALR cells 
were collected and the concentration of total (C) and specific (D) primary bile acids was determined 
using LC-MS/MS and normalized to protein concentration. p<0,05 * compared to untreated HepG2 
cells, # compared to untreated HepG2-sfALR cells, + compared to the corresponding treated HepG2 
cells.  
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3.2. sfALR represses CYP7A1 via activating STAT3 and thereby inhibiting 
HNF4α 
The expression and therefore activity of CYP7A1 undergo tight regulation by various 
transcription factors. Since HNF4 is known to activate CYP7A1 expression, we 
aimed to analyze its expression in HepG2 and HepG2-sfALR cells using qRT-PCR. 
As shown in Fig. 2A, a significant decrease in the expression of HNF4 in 
HepG2-sfALR cells was observed (approx. 67%). This reduction was confirmed by 
western blot showing a reduction in HNF4 protein in HepG2-sfALR compared to 
HepG2 cells (Fig. 2B). It has been previously shown that HNF4α is downregulated 
upon phosphorylation of STAT3 on tyrosine 705 [10]. Therefore, we aimed to assess 
the phosphorylation of STAT3 in HepG2-sfALR cells after treatment with GCDCA. As 
shown in Fig. 2B, STAT3 phosphorylation is higher in HepG2-sfALR compared to 
HepG2 cells. Our data suggest that sfALR modulates CYP7A1 expression, at least 
partially, by activating STAT3 and thereby downregulating HNF4. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Diminished CYP7A1 expression in HepG2-sfALR is attributed to the activation of STAT3 and 
absence of HNF4α. HepG2 and HepG2-sfALR cells were incubated for 24 hours with or without 
100 µM of the respective bile acid, (A) mRNA levels of HNF4α were analyzed by qRT-PCR with HPRT 
as housekeeping gene and normalized to untreated HepG2. (B) Total protein was isolated and protein 
expression of HNF4α, pSTAT3, STAT3 and -actin were analyzed by western blot techniques. 
Immunoblots from 3 different experiments were analyzed by densitometric analysis and one 
representative is shown. p<0,05 * compared to untreated HepG2 cells, + compared to GCDCA-treated 
HepG2 cells. 
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3.3. Over-expressed sfALR decreases the bile acid-induced apoptosis 
Several toxic bile acids were shown to contribute to liver injury by inducing apoptosis. 
Therefore the activity of caspase 3/7 was investigated in HepG2 and HepG2-sfALR 
cells after treatment with GCDCA and/or apoptosis-inducer TRAIL (TNFα-related 
apoptosis inducing ligand). GCDCA was chosen for the assays due to its known 
toxicity and elevated concentrations in patients with cholestasis [30]. As shown in 
Fig. 3A, HepG2-sfALR cells showed lower caspase 3/7 activity (approx. 70%) before 
and after treatment with GCDCA or TRAIL compared to their corresponding HepG2 
cells. Furthermore, the combination of GCDCA and TRAIL induced caspase 3/7 
activity in both HepG2 and in HepG2-sfALR cells by 3 folds. However, GCDCA and 
TRAIL-treated HepG2-sfALR show a 30% reduction in caspase 3/7 activity when 
compared to the similarly treated HepG2 cells. This finding suggests that 
over-expressed cytosolic sfALR has a protective effect against apoptosis under 
cholestatic conditions. 
To elucidate the mechanism of the anti-apoptotic effect of sfALR, the expression of 
the TRAIL death receptors, DR5 and DR4, was determined in HepG2-sfALR and 
HepG2 cells in absence of presence of GCDCA. A decreased expression of DR5 in 
HepG2-sfALR cells was noted after treatment with GCDCA compared to HepG2 cells 
(Fig. 3B). On the other hand, no different expression in DR4 was seen after treatment 
with GCDCA in both cell lines (Fig. 3C). Furthermore, FASR expression, known to be 
involved in bile acid-induced apoptosis, was not altered in HepG2-sfALR cells after 
GCDCA treatment compared to HepG2 cells (Fig. 3C). Our data suggest that sfALR 
protects hepatocytes from bile acid- and TRAIL-induced apoptosis at least in part by 
downregulating DR5 expression. 
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Fig. 3. Over-expressed sfALR protects the cells from TRAIL-induced apoptosis by downregulating 
DR5 expression. (A) HepG2 and HepG2-sfALR cells were incubated with or without 100 µM GCDCA 
for 24 hours. After 6 hours treatment with death receptor ligand TRAIL (25 ng/ml), caspase 3/7 activity 
was determined. HepG2 and HepG2-sfALR cells were incubated with GCDCA for 24 hours and total 
protein was isolated to analyze protein expression of DR5 (B), DR4 and FASR (C) by western blot 
(-actin and GAPDH served as loading controls). Immunoblots from 3 different experiments were 
analyzed by densitometric analysis and one representative is shown. p<0,05 * compared to untreated 
HepG2 cells, # compared to untreated HepG2-sfALR cells,+ compared to corresponding treated 
HepG2 cells.  
 
3.4. ALR exhibits its anti-apoptotic effects via activation of STAT3 
Known to regulate the expression of DR5, the activation of both NFкB and STAT3 
was assessed in HepG2 and HepG2-sfALR cells. As shown in Fig. 4A (see also Fig. 
2B), the tyrosin phosphorylation of STAT3 (a repressor for DR5 expression), but not 
expression, was increased with or without GCDCA treatment in HepG2-sfALR 
compared to HepG2 cells. The importance of pSTAT3 for the protective effects of 
 Chapter 5 
 
109 
sfALR was also investigated by the use of the tyrphostin tyrosine kinase inhibitor 
AG490 that has been extensively used for inhibiting JAK2 (Janus Kinase 2) and 
thereby the phosphorylation of STAT3 [31] without affecting STAT3 expression. A 
measurement of caspase 3/7 activity in HepG2-sfALR cells showed an overall 
increase in the caspase 3/7 activity in the AG490-treated cells with or without adding 
TRAIL and/or GCDCA (Fig. 4B). In addition, the expression of DR5 was increased in 
HepG2-sfALR after treatment with AG490 and GCDCA compared to HepG2-sfALR 
treated only with GCDCA (Fig. 4C). Additionally, the activation of NFкB (a DR5-
inducer) was analyzed in HepG2-sfALR cells. Fig. 4D shows that NFкB activation is 
not altered in HepG2-sfALR. Taken together, these results demonstrate that the 
protective effects of sfALR are attributed to the activation of STAT3 which leads to a 
decreased DR5 expression and therefore protecting the liver from DR5-mediated 
apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Over-expressed sfALR exhibits its anti-apoptotic effects via activation of STAT3. (A) HepG2 
and HepG2-sfALR cells were incubated with GCDCA for 24 hours and total protein was isolated to 
analyze protein levels of pSTAT3 and STAT3 (ß-actin served as a loading control). (B) HepG2-sfALR 
cells were incubated with or without 100 µM GCDCA and/or AG490 for 24 hours. After treatment with 
25 ng/ml TRAIL for 6 hours caspase 3/7 activity was analyzed. p<0,05 * compared to untreated 
HepG2-sfALR cells, # compared to corresponding HepG2-sfALR cells. (C) HepG2-sfALR cells were 
incubated with 100 µM GCDCA and/or AG490 for 24 hours and total protein was isolated to analyze 
protein expression of DR5 and ß-actin by western blot techniques. (D) After treatment of HepG2 and 
HepG2-sfALR cells with GCDCA for 24 hours, nuclear extracts were prepared and total as well as 
phosphorylated NFкB (p65) were analyzed by western blotting (HDAC1 served as a loading control). 
One representative immunoblot out of 3 different experiments is shown.  
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3.5. Reduced ALR expression in liver tissue from patients with cholestasis 
Previous results indicate that enhanced levels of cytosolic sfALR lead to reduced 
apoptosis and reduced bile acid pool, therefore we aimed to investigate the 
expression of ALR in hepatic tissues under cholestatic conditions. mRNA expression 
of ALR in 13 normal liver tissues were compared to 45 samples collected from 
patients with histopathological proven cholestasis. ALR expression is significantly 
reduced in cholestatic (0,46±0,22) compared to normal liver samples (1,01±0,44) 
(Fig. 5A). Furthermore, ALR is inversely expressed compared to bilirubin serum 
levels (ALR expression in patients with bilirubin <1mg/dL (n=14): 1,01±0,44 vs. 
patients with bilirubin ≥1 mg/dL (n=44) 0,45±0,22) with a p<0,05. However, no 
correlation was detectable between ALR expression and serum ALP (Alkaline 
phosphatase), ALT (Alanine transaminase) or GGT (Gamma-glutamyltransferase). 
Moreover, ALR protein expression was investigated in normal liver tissue (n=4) and 
liver tissue collected from patients with cholestasis (n=5) (Fig. 5B). Western blot 
analysis confirms our mRNA study demonstrating a reduction of primarily sfALR (15 
kDa) protein expression in cholestatic liver tissue. Furthermore, we analyzed the 
mRNA expression of ALR and FOXA2 (Forkhead Box A2, an inducer of ALR 
expression [32]) in primary human hepatocytes isolated from 3 normal and 8 
cholestatic liver tissues. Interestingly, the expression of ALR positively correlates with 
FOXA2 expression (r=0,900) (Fig. 5C). 
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Fig. 5. Reduced ALR mRNA expression in liver tissues collected from patients 
with cholestasis. (A) Expression of ALR mRNA was analyzed by qRT-PCR in liver tissue samples from 
patients with histopathological proven cholestasis (n=45) and normal liver tissue (n=13), median is 
indicated with a black bar. * p<0,05 compared to normal liver tissues. (B) Protein expression of ALR 
was analyzed by western blotting in liver tissue samples from patients with histopathological proven 
cholestasis (n=5) and normal liver tissue (n=4). (C) Primary human hepatocytes (PHH) were isolated 
from normal (n=3) and cholestatic (n=8) liver tissues and mRNA expression of ALR and FOXA2 was 
analyzed by qRT-PCR technique and normalized to YWHAZ. A correlation plot of ALR and FOXA2 
mRNA expression is shown with best fit line for normal (n=3) and cholestatic (n=8) liver tissue 
samples (r=0,900). Insert demonstrates a magnification of the samples with an mRNA expression 
below 0,5 [gene expression/YWHAZ]. 
 
4. Discussion 
Augmenter of liver regeneration (ALR), a hepatotrophic co-mitogen, was shown to 
play a pivotal role in liver regeneration in vivo [33, 34]. After partial hepatectomy, ALR 
was found to be upregulated in the liver [35]. Additionally, it was previously 
demonstrated that ALR can modulate hepatic metabolism [36]. Furthermore, it was 
shown that over-expression of sfALR alters IL6-signaling by inducing STAT3 
phosphorylation [24], counteracts palmitic acid-induced apoptosis and reduces both 
ER stress and PA-induced DR5 expression [20].  
Cholestatic liver diseases are pathophysiologic syndromes, caused by different 
etiologies [1, 2] and defined as an impaired bile flow from the liver. The accumulation 
of cytotoxic bile acids activates different signaling pathways and interrupts multiple 
metabolic processes [37] thereby the transcriptional regulation of CYP7A1, the 
rate-limiting enzyme of the classical pathway in bile acids synthesis, has received 
great attention. Furthermore, many studies were dedicated to understanding the 
molecular mechanism of cholestatic injury [38]. Bile acid-induced apoptosis is 
considered the main cause of injury [13, 15, 39]. It has been shown that both Fas 
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receptor (FasR) and TRAIL-Receptor 2 (DR5) are involved in bile acid-induced 
apoptosis [11, 13, 15, 40, 41]. 
The regulation of CYP7A1 by bile acids has been well described [9, 42, 43]. The 
FXR/SHP/HNF4α feedback loop is considered the main pathway of bile 
acid-mediated negative feedback [9, 42, 44, 45]. We found that the expression and 
activity of CYP7A1, but not CYP27A1, are reduced under conditions of high cytosolic 
sfALR. Interestingly, the expression of HNF4, an activator of CYP7A1, was also 
decreased in HepG2-sfALR cells. A previous study has shown that activation of 
STAT3 results in a reduced CYP7A1 and CYP27A1 expression [46]. Moreover, 
STAT3Δhc mice (specific ablation of STAT3 in mouse hepatocytes and 
cholangiocytes) show an increased bile acid pool [47]. Interestingly, over-expression 
of cytosolic sfALR was shown to increase the activation of STAT3 by increasing the 
tyrosine phosphorylation upon IL6 treatment [24]. On the other hand, STAT3 
phosphorylation was shown to activate miRNA24 and miRNA629 which in turn 
reduce the expression of HNF4α, a main activator of CYP7A1 [10]. Thereby we 
postulate that high levels of cytosolic sfALR, through activating STAT3 
phosphorylation, reduce the expression of HNF4α and thus repress the expression of 
CYP7A1 and bile acids production. 
Bile acids induce liver injury by apoptosis in a death receptor-dependent and 
-independent mechanisms [11, 12]. Upon treatment with deoxycholic acid (DCA), 
DR5 expression is increased, whereas DR4 remains unchanged, due to the 
activation of JNK pathway and the activation of SP1 binding to its response element 
within DR5-promoter [12]. Higuchi et al. have also shown that GCDCA treatment in 
vitro increased the DR5 expression and thus increased apoptosis [11]. In addition, 
sfALR expression reduces the activation of JNK upon treatment with free fatty acid 
[20]. Although HepG2-sfALR cells showed a 30% reduction in caspase 3/7 activity 
compared to HepG2 cells, the combination of TRAIL and GCDCA treatment lead to a 
3 fold increase in caspase 3/7 activity in both cells lines, which suggests that sfALR 
anti-apoptotic effects are independent from the activation of JNK pathway by GCDCA 
treatment. Nevertheless, over-expressed sfALR preserved the reduced apoptosis 
even under extreme cholestatic conditions (high concentrations of GCDCA and 
TRAIL). It is worthwhile to mention that the expression of NTCP (sodium taurocholate 
co-transporting polypeptide, responsible for the uptake of bile acids into hepatocytes) 
is induced by HNF4α [48], which might explain the reduced caspase 3/7 activity in 
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GCDCA treated HepG2-sfALR cells due to reduced HNFα4 levels. Furthermore, 
Denk and colleagues have shown that transfection of the 23 kDa isoform of ALR 
(located in the intermembrane space of mitochondria) into Huh7 cells 
over-expressing NTCP did not reduce the GCDCA-induced apoptosis [49] which may 
confirm the different roles of ALR isoforms. In the current study we used HepG2 cells 
that possess 40% of normal liver’s content of OATP (organic anion transporting 
polypeptide) which mediates hepatocellular uptake of bile acids [50]. Interestingly, 
using HepG2-NTCP cells diminished the protective effect of ALR (data not shown) 
which suggests that endogenous sfALR exerts its anti-apoptotic effects by regulating 
death receptors and is not able to reduce the toxicity induced by accumulation of 
intracellular bile acids. We identified DR5 as the death receptor responsible for the 
reduced apoptosis in HepG2-sfALR. The expression of DR5 is reduced by the 
activation of STAT3 [51]. STAT3 activation, characterized by tyrosine (705) 
phosphorylation, is increased by over-expression of sfALR. Interestingly, blocking 
STAT3 activation by JAK2 inhibition increased DR5 expression and caspase 3/7 
activity in HepG2-sfALR cells. Furthermore, NFкB activation was shown to induce 
DR5 expression [52], but we did not find any altered NFкB activation in HepG2-sfALR 
cells compared to HepG2 cells. Taken together, we hypothesize that sfALR’s 
anti-apoptotic effects are attributed, at least in part, to its ability to maintain the 
activation of STAT3 and thereby reducing DR5 expression and cell sensitivity 
towards extrinsic death signals like TRAIL. 
It is worth to mention that GCDCA reduces the phosphorylation of STAT3 by 
diminishing gp130 (IL6 receptor) expression. This contributes to the hepatotoxic 
effects of bile acids by eliminating the positive effects of IL6 signaling on liver 
regeneration under cholestatic conditions [53]. Furthermore, liver specific gp130 
knock-out mice that underwent bile duct ligation showed impaired acute-phase 
response leading to reduced survival and an increase of bacterial growth in the bile 
and the liver [54]. Therefore we postulate that the induction of sfALR expression in 
hepatocytes during cholestasis might possibly serve in a preserved STAT3 activation 
and thereby a better protection against secondary biliary infections. However, the 
molecules involved in STAT3 activation by sfALR are still unknown. It was previously 
shown that sfALR-HepG2 cells show increased STAT3 phosphorylation at tyrosin 
(705) whereas STAT3 phosphorylation at serine (727) as well as total STAT3 remain 
unchanged [24]. In addition, it was shown that repressors of STAT3 signaling like 
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PIAS3 (protein inhibitors of STATs 3) as well as SOCS3 (suppressor of cytokines 
signaling 3) remain unchanged in HepG2-sfALR cells [24]. Therefore, investigating 
the molecules that link over-expressed sfALR with STAT3 activation is of great 
importance. 
Moreover, in this study we found reduced hepatic ALR mRNA and protein expression 
in patients with cholestasis compared to normal liver tissues. Furthermore, ALR 
expression correlated strongly with FOXA2 expression in primary human hepatocytes 
(an inducer of ALR expression).This is in line with a report showing that the 
expression of FOXA2 is reduced in patients with cholestasis and in rodent models of 
cholestasis [55, 56]. Taken together, we may postulate that FOXA2 deficiency leads 
to reduced cytosolic ALR expression resulting in aggravating cholestatic injury by 
increased accumulation of bile acids, increased DR5 expression and therefore 
susceptibility of hepatocytes to apoptosis. The detrimental effects of bile acids might 
be thereby reversed by elevating ALR levels in hepatocytes which suggests ALR as 
a possible target for therapy in cholestatic liver diseases.  
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Abstract 
Bile acids are both amphiphilic agents that facilitate lipid absorption and signaling 
molecules that regulate different cellular process. Bile acid synthesis is restricted to 
hepatocytes and is rate-limited by CYP7A1 (cholesterol 7α hydroxylase). CYP7A1 
undergoes tight regulation through different transcription factors and is repressed 
after partial hepatectomy in rodents to prevent the accumulation of toxic bile acids in 
the remaining hepatocytes. Augmenter of Liver Regeneration (ALR) is a 
hepatotrophic factor that was shown to be increased after partial hepatectomy. 
Nevertheless, little is known about the role of ALR in regulating CYP7A1 expression 
and therefore potentially protecting hepatocytes from bile acid accumulation and bile 
acid-induced apoptosis. Therefore, human hepatocytes were incubated with 
recombinant human ALR (rhALR) and the expression of CYP7A1 as well as bile 
acid-induced apoptosis were analyzed. We found that application of rhALR reduces 
CYP7A1 expression by reducing the expression of its transcriptional activator CAR 
(Constitutive Androstane Receptor). Moreover, rhALR reduced apoptosis induction 
by toxic concentrations of bile acids (intrinsic apoptosis) but showed no effect on the 
expression of death receptor 5 (DR5) or the extrinsic apoptosis (ligand-dependent 
apoptosis) under cholestatic conditions. Taken all together, rhALR might contribute to 
protecting hepatocytes from toxic concentrations of bile acids and thereby this 
suggests a new role of ALR in augmenting the process of liver regeneration. 
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1. Introduction 
Bile acids are physiological detergents that facilitate the absorption and transport of 
sterols and lipid-soluble vitamins as well as the disposal of toxic metabolites and 
xenobiotics [1]. The synthesis of bile acids is restricted to the liver and proceeds via 
either neutral or acidic pathway [2]. The first and rate-limiting enzyme of the classical 
pathway is cholesterol 7 hydroxylase (CYP7A1, cytochrome P450 7A1) [3]. 
CYP7A1 expression is inhibited by bile acids returning to the liver via enterohepatic 
circulation [3]. Due to their amphiphilic nature, bile acids concentrations in 
hepatocytes are tightly regulated to prevent their toxic effects [1]. bile acids activate 
their nuclear receptor FXR (Farnesoid X Receptor) that induces the expression of 
Small Heterodimer Partner (SHP) which then represses the expression of CYP7A1 
[4]. Moreover, it has been reported that CYP7A1 is repressed upon partial 
hepatectomy and after liver damage in both animals and patients [5-7]. This 
repression lowers bile acids concentration and protects remaining hepatocytes from 
accumulating toxic bile acids [8]. Earlier studies have shown that Hepatocyte Growth 
Factor (HGF) is involved in the repression of CYP7A1 in hepatocytes [8]. Additionally 
CYP7A1 over-expression in mice impaired liver regeneration after partial 
hepatectomy and caused increased hepatocyte death [9], probably due to induced 
apoptosis in hepatocytes through different mechanisms [10-14]. Augmenter of liver 
regeneration (ALR) is a hepatotrophic factor [15] that has recently gained grown 
interest, ALR is found in hepatocytes in 3 isoforms: 23, 21 and 15 kDa [16]. Its 
15 kDa accumulates in the liver upon partial hepatectomy and liver injury [17] and 
during liver regeneration [17, 18]. A previous study by our group also showed 
increased ALR expression in livers from patients with HCC (hepatocellular 
carcinoma) and CCC (cholangiocyte carcinoma) compared to normal liver tissue [19]. 
Furthermore, recombinant ALR (rALR) alters different P450 isoenzyme activities [20] 
and exerts liver-specific anti-apoptotic effects [21]. Nevertheless, it is not clear 
whether this highly liver-specific protein is involved in the protection of hepatocytes 
from cytotoxic bile acids by repression of CYP7A1 or reducing bile acid-induced 
apoptosis upon liver damage. In this study we show that rhALR represses the 
expression of CYP7A1 through the activation of NFB (Nuclear Factor 'kappa-light-
chain-enhancer' of activated B-cells) and also reduces the activity of caspase 3/7 in 
hepatoma cells upon treatment with toxic bile acids. 
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2. Materials and methods 
2.1. Cell culture and treatments 
The human hepatoma cell line HepG2 was obtained from American Type Culture 
Collection (HB-8065, ATCC, Manassas, VA) and grown at 37°C, 5% CO2 in DMEM 
(BioWhittaker, Verviers, Belgium) supplemented with penicillin (100 units/ml), 
streptomycin (10 μg/ml) and 10% fetal calf serum (Biochrom, Berlin, Germany). The 
recombinant human short form (15 kDa) ALR (rhALR) was prepared as described 
previously [19]. Cells were seeded at a density of 5x104 cells/cm2, starved for 
24 hours and treated with indicated concentrations of rhALR for 24 hours. Primary 
human hepatocytes (PHH) were isolated and cultured as reported previously [22], 
starved for 24 hours and treated with indicated concentrations of rhALR for 24 hours. 
For Caspase 3/7 assays, 100 µM glycodeoxycholic acids (GCDCA) (Sigma-Aldrich, 
St-Louis, MO) and/or 25 ng/ml TRAIL (Abcam, Cambridge, UK) were applied to cells 
for 24 and 6 hours respectively. mRNA and protein samples were isolated for further 
analysis. 
 
2.2. RNA isolation, reverse transcription and qRT-PCR 
Total RNA was isolated using RNeasy Mini Kit (Qiagen, Hilden, Germany). One μg of 
total RNA was reverse-transcribed using the Reverse-Transcription System (Qiagen, 
Hilden, Germany). Transcript levels of CYP7A1, CYP27A1, FXR, SHP, HNF4α, CAR 
and HPRT were quantified using real-time PCR technology (Roche, Penzberg, 
Germany). Amplicons were verified by sequence analysis and each quantitative PCR 
was performed in duplicates for 3 sets of RNA preparations. Primers used for 
qRT-PCR are listed in Table (I). 
 
2.3. SDS-PAGE and immunoblotting 
Total protein fractions (30 μg per lane) were separated by 12% SDS-PAGE (Biorad, 
Hercules, CA, USA) under reducing conditions using 100 mM DTT. Proteins were 
transferred onto PVDF membranes (Biorad, Hercules, CA, USA), incubated with 
specific antibodies and developed with ECL reactions (Pierce, Rockford, IL, USA). 
Following antibodies were used: anti pNFB (p-p65), (#8242), anti-NFB (p65) 
(#3033) and anti--actin (#4970) all obtained from Cell Signaling (Danvers, MA). Anti-
HDAC1 (#05-100) purchased from Millipore, Merck, Darmstadt, Germany, anti-death 
receptor 5 (DR5) (#ab8416) was obtained from Abcam (Cambridge, UK). Secondary 
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goat HPR-conjugated antibodies were obtained from Dako (Hamburg, Germany) 
(anti-rabbit # P0448 and anti-mouse #P0447). 
 
Table (I): Primers used for qRT-PCR  
CYP7A1, sense 5'-gaatgctggtcaaaaagtc-3' 
CYP7A1, antisense 5'-tgaaatcctccttagctgt-3' 
CYP27A1, sense 5'-cacaaactcccggatcat-3' 
CYP27A1, antisense 5'-aggctcagagaaggcagt-3' 
FXR, sense 5'-tacatgcgaagaaagtgtcaaga-3' 
FXR, antisense 5'-actgtcttcattcacggtctgat-3' 
SHP, sense 5'-ggtgcccagcatactcaagaa-3' 
SHP, antisense 5'-ggacttcacacagcacccagt-3' 
HNF4, sense 5'-tgtcccgacagatcacctc-3' 
HNF4, antisense 5'-cactcaacgagaaccagcag-3' 
CAR, sense 5'-tgatcagctgcaagaggaga-3' 
CAR, antisense 5'-aggcctagcaacttcgcata-3' 
HPRT, sense 5'-tgacactggcaaaacaatgca-3' 
HPRT, antisense 5'-ggtccttttcaccagcaagct-3' 
 
2.4. Caspase 3/7 activity 
Following treatments, cells were subjected to Caspase 3/7 activity measurement 
using Caspase-Glo 3/7 Assay (Promega, Madison, USA) according to the 
manufacturer's instructions. 
 
2.5. Statistical analysis 
All data are presented as mean plus/minus standard deviation of the mean. Data 
were compared between groups using the student t-test. p value of < 0,05 was 
considered significant. 
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3. Results 
3.1. Exogenous rhALR reduces the expression of CYP7A1 but not CYP27A1 
Initially, we analyzed the potential effect of exogenous rhALR (15 kDa) on the 
classical and alternative pathway of bile acid de novo synthesis. Therefore mRNA 
expression of CYP7A1 and CYP27A1 (mitochondrial 27-hydroxylase), the 
rate-limiting enzymes of the classic and alternative pathways of bile acid synthesis 
respectively, was analyzed by qRT-PCR in HepG2 cells with or without rhALR. 
rhALR treated-HepG2 cells showed a significantly reduced CYP7A1 expression 
compared with untreated HepG2 cells after 12 and 24 hours of incubation (Fig. 1A). 
In addition, the mRNA expression of CYP27A1 showed no significant change in 
HepG2-sfALR cells (Fig. 1B) which suggests that rhALR reduces only the expression 
of CYP7A1. 
 
 
 
Fig. 1. Effect of exogenous rhALR on the expression of de novo synthesis enzymes. HepG2 cells were 
starved for 24 hours and then incubated with 100 ng/ml of rhALR for 6, 12 and 24 hours. mRNA levels 
of (A) CYP7A1 and (B) CYP27A1 were analyzed by qRT-PCR and normalized to HPRT. * p<0,05 
compared to the corresponding untreated HepG2 (three independent experiments, Mean±SD). 
 
3.2. Exogenous rhALR reduces the expression of CYP7A1 repressor, FXR 
In order to elucidate which transcription factors mediate CYP7A1 repression, mRNA 
expression of FXR, SHP and HNF4α (hepatocyte nuclear factor 4) was analyzed. 
The activation of FXR leads to inducing SHP that blocks the HNF4-mediated 
activation of CYP7A1. As shown in Fig. 2A, mRNA levels of FXR were significantly 
reduced after 24 hours of ALR incubation. Moreover, SHP (Fig. 2B) and HNF4α 
(Fig. 2C) showed no change in expression. Therefore, the reduction of CYP7A1 by 
rhALR seems to be independent of FXR, SHP or HNF4α. 
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Fig. 2. rhALR reduces the expression of FXR without reducing the expression of SHP and HNF4α. 
HepG2 cells were incubated after 24 hours starvation with 100 ng/ml rhALR for 6, 12 and 24 hours. 
mRNA levels of (A) FXR, (B) SHP and (C) HNF4α were analyzed by qRT-PCR and normalized to 
HPRT. * p<0,05 compared to the corresponding untreated HepG2 (three independent experiments, 
Mean±SD). 
 
3.3. Exogenous rhALR reduces the expression of CAR via NFB activation  
CAR activation was proved to activate bile acid synthesis and prevent the formation 
of cholesterol gallstones [23]. Additionally, rhALR negatively regulates the expression 
of CAR by activating NFB [20]. Therefore, CAR expression was analyzed upon 
rhALR treatment. As shown in Fig. 3A, CAR is repressed by rhALR after 12 and 
24 hours of incubation. NFB activation and translocation into the nucleus is 
increased in the nuclear fractions of rhALR treated-HepG2 cells (Fig. 3B). These 
results indicate that reduction of CYP7A1 by rhALR may be mediated by repressing 
CAR expression via NFB activation. 
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Fig. 3. rhALR reduces the expression of CYP7A1-activator CAR by activating NFB. HepG2 cells were 
starved for 24 hours and then treated with 100 ng/ml rhALR for 6, 12 and 24 hours. (A) mRNA 
expression of CAR was analyzed by qRT-PCR and normalized to HPRT. * p<0,05 compared to the 
corresponding untreated HepG2 (three independent experiments, Mean±SD). (B) Nuclear extracts of 
HepG2 cells were prepared after 24 hours treatment with rhALR (100 ng/ml), the phosphorylation of 
NFB was assessed using western blot technique. Three different experiments were analyzed by 
densitometric analysis and a representative immunoblot is illustrated. * p<0,05 compared to the 
corresponding untreated HepG2 cells. 
 
3.4. Exogenous rhALR reduces caspase 3/7 activity upon treatment with high 
concentrations of toxic GCDCA independent from DR5 regulation 
Several bile acids were shown to contribute to apoptosis in a death 
receptor-dependent mechanism or by activating intrinsic apoptotic pathways. In order 
to assess rhALR effect on the apoptotic signals induced by bile acids, caspase 3/7 
assay was performed under conditions of cytotoxic concentrations of GCDCA and/or 
extrinsic apoptosis-inducer (TRAIL). As shown in Fig. 4A, rhALR treated-HepG2 cells 
show a decreased caspase 3/7 activity prior to any treatment. Whereas rhALR 
significantly reduced apoptosis caused by toxic GCDCA, it showed no efficacy in 
reducing extrinsic apoptosis induced by TRAIL. Furthermore, the combination of 
TRAIL and GCDCA induced caspase 3/7 activity in rhALR-treated HepG2 cells 
significantly more than their corresponding HepG2 cells without rhALR treatment. 
Since TRAIL-induced apoptosis is mediated by death receptor 5 (DR5), the 
expression of DR5 was analyzed in primary human hepatocytes and human 
hepatoma cells (HepG2) upon treatment with different concentrations of rhALR. 
Figures 4B and 4C demonstrate that DR5 expression remains unchanged upon 
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rhALR treatment. These data suggest the rhALR contributes to the protection of 
hepatocytes against bile acid-induced apoptosis in a DR5-independent mechanism.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Exogenous rhALR reduces caspase 3/7 activity upon treatment with high concentrations of 
toxic GCDCA independent from DR5 regulation. (A) HepG2 cells were starved for 24 hours and 
pre-treated with 100 ng/ml rhALR. Later 100 µM GCDCA and/or apoptosis-inducer TRAIL were added 
for 24 and 6 hours respectively, followed by Caspases 3/7 activity assay.* p<0,05 compared to 
untreated HepG2, # compared to rhALR treated-HepG2, + compared to corresponding HepG2 without 
rhALR treatment (three independent experiments, Mean±SD). (B) Primary human hepatocytes were 
starved for 24 hours and then treated with 50 or 250 ng/ml rhALR, total protein was then isolated to 
measure protein levels of DR5 and -actin by western blot techniques. (C) HepG2 cells were starved 
for 24 hours and then treated with 100 ng/ml of rhALR, total protein was isolated to measure the 
protein levels of DR5 and -actin by western blot techniques. 
 
4. Discussion 
Liver regeneration is a well-orchestrated process, driven by the action of several 
cytokines and growth factors e.g. HGF and EGF [24]. The regeneration-promoting 
effects of those molecules have been demonstrated and characterized using different 
in vivo and in vitro models [25, 26]. Among the co-mitogens is ALR which was shown 
to accumulate in regenerating livers and to augment liver regeneration in response to 
tissue loss or damage [19, 27]. Compared to other growth factors, ALR has proven to 
exert its actions primarily on hepatocytes and hepatoma cells [17, 28]. Furthermore, 
ALR has been previously shown to alter hepatic P450-metabolizing enzyme activities 
in a dose dependent manner [20]. 
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Huang et al have demonstrated that partial hepatectomy (PH) increases bile acids 
flux and causes metabolic stress [29]. Two parallel mechanisms cooperate to insure 
the protection of hepatocytes from toxic bile acids after PH, first: FXR activates the 
liver regeneration and second: CYP7A1 expression is strongly repressed. The 
importance of CYP7A1 repression during the acute phase of liver regeneration has 
been further confirmed by infecting mice with a CYP7A1-expressing adenovirus 
followed by 70% PH. Indeed, liver regeneration was repressed in mice 
overexpressing CYP7A1 [9] which suggests that CYP7A1 repression is essential 
during early stages of liver regeneration to protect hepatocytes from cell death and 
damage. Furthermore, in vitro work of Song et al. [8] and Kakizaki et al. [30] indicated 
that HGF represses CYP7A1 expression in an SHP-dependent and SHP-
independent pathways. Nevertheless, it is not clear whether the liver-specific growth 
factor ALR contributes to CYP7A1 repression upon PH. Therefore, we aimed in this 
study to analyze the effect of ALR on CYP7A1 expression. In this study we show that 
treatment of HepG2 cells with rhALR leads to reduced CYP7A1 expression. On the 
other hand, CYP27A1, the rate-limiting enzyme in the alternative pathway of bile 
acids synthesis, remained without significant change. The repression of CYP7A1 by 
FXR/SHP has been extensively analyzed in several studies [4, 31] therefore the 
expression of FXR and SHP was analyzed upon rhALR treatment. Unlike SHP, FXR 
expression was reduced after rhALR-treatment which suggests that ALR-mediated 
repression of CYP7A1 is FXR/SHP independent. 
Interestingly, treatment of primary mouse hepatocytes with TNF, a typical NFB 
inducer, suppressed CYP7A1 expression while leaving FXR-target genes unchanged 
[32]. Moreover, rhALR was shown to modulate the hepatic P450-metabolizing 
enzymes activities by activating NFB [20]. Therefore, we investigated the activation 
and translocation of the p65 subunit of NFB into the nucleus after rhALR treatment 
and found increased p65 in the nuclear fractions of rhALR-treated HepG2 cells. In 
addition, CAR activation was shown to induce CYP7A1 expression and thereby 
reduce the formation of cholesterol gallstones [23]. Furthermore, IL6 treatment was 
confirmed to repress P450 genes by down-regulation of CAR and PXR, nuclear 
receptor family members that regulate P450 gene expression [33]. Additionally, NFB 
activation by TNF was shown to reduce the transactivation of HNF4α by 
downregulating its AF1 and AF2 domains [34]. Therefore, we analyzed the 
expression of CYP7A1 inducers: HNF4 and CAR in rhALR-treated HepG2 cells. 
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While HNF4 remains without significant change, CAR is significantly reduced after 
12 and 24 hours of rhALR treatment. This suggests that rhALR exerts its repression 
on CYP7A1 by activating NFB and reducing the transactivation of CYP7A1 by CAR. 
Bile acid-induced apoptosis contributes to cholestatic liver injury. Bile acids induce 
apoptosis in a death-receptor dependent mechanism [10, 13, 14], in particular 
TRAIL-R2 (or death receptor 5, DR5) and FAS receptors (FASR). Moreover, 
Micromolar concentrations of GCDCA induce mitochondrial release of cytochrome C 
by FASR-dependent and -independent pathways [35]. Mitochondrial release of 
cytochrome C is dependent on Bax, a pro-apoptotic protein. Rodrigues et al. [36] 
demonstrated that Bax-translocation into mitochondria initiates the mitochondrial 
permeability transition (MPT) and cytochrome C release during 
deoxycholate-induced apoptosis. Interestingly, we have shown previously that upon 
free fatty acid treatment, rhALR reduces apoptosis accompanied by reducing Bax 
protein expression. On the other hand, NFB activation by cytokines protected rat 
hepatocytes against bile acid-induced apoptosis. Furthermore, NFB inhibition by 
genetic or pharmacological approaches rendered Hela cells more susceptible to 
TNF-induced apoptosis [37]. Interestingly, rhALR reduces cytochrome C release 
from mitochondria caused by ethanol treatment [21]. Therefore we investigated the 
ability of rhALR to reduce bile acid-induced apoptosis and found that rhALR treated 
cells show lower caspase 3/7 activity. In addition, treatment with toxic concentrations 
of GCDCA induced apoptosis but this induction was reduced upon rhALR treatment. 
On the other hand, TRAIL-induced apoptosis was not reduced by rhALR addition and 
DR5 expression was not altered by rhALR treatment. Therefore, we hypothesize that 
rhALR could contribute to protecting cells against bile acid-induced apoptosis by 
activating NFB and reducing Bax protein levels and therefore reducing cytochrome 
C release without effecting the expression of DR5. In conclusion, rhALR induction 
upon liver injury may contribute to protecting hepatocytes from toxic bile acids by 
(i) reducing the synthesis of bile acids by repressing CYP7A1 expression and (ii) by 
reducing bile acid-induced apoptosis. Therefore, ALR protects hepatocytes from 
developing intra-hepatic cholestasis in acute stages of liver regeneration.  
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1. Summary  
It was in 1994 when the term “Augmenter of Liver Regeneration (ALR)” was first 
coined to describe a protein that augments the proliferative response of the liver after 
partial hepatectomy in rats and dogs. Since then extensive work has been attributed 
to identify the expression of ALR’s different isoforms and exploring their 
localization-dependent functions. In the human liver, ALR is expressed in 
hepatocytes and cholangiocytes. Specifically, the long forms of ALR (lfALR, 23 and 
21 kDa) have been identified in the cytosol and mitochondria where it acts as a 
disulfide relay system coupled to the oxidoreductase Mia40 for facilitating protein 
import into mitochondria. Additionally, the short form of ALR (sfALR, 15 kDa) was 
detected solely in the cytosol with some reports suggesting its release into serum 
upon hepatic injury. Upon release, ALR binds to its receptor and activates different 
signaling pathways. Depending on its localization, the dual signaling pathways of 
sfALR have been investigated and were found to be differential in various 
pathological models for various liver injuries (chapter 1). 
Cholestasis represents pathophysiologic syndromes defined as an impaired bile flow 
from the liver due to, among others, gallstones, local tumors and the genetic 
deficiencies in bile acids exporters. Regardless of the cause, the accumulation of 
toxic bile acids leads to liver injury by initiating apoptosis, ER-stress, mitochondrial 
instability and inflammatory response due to activation of neutrophils and Kupffer 
cells. Therefore, the regulation of ALR expression by bile acids (chapter 3) and 
cholestasis-related cytokines (IL1) (chapter 4) have been investigated and found 
that under cholestatic conditions, ALR expression is attenuated due to the activation 
of SHP (Small Heterodimer Partner) by bile acids (chapter 3). Furthermore, IL1 
release from activated Kupffer cells also leads to reduced ALR expression that could 
be attributed to reduced SP1 expression and diminished Egr-1 binding to its binding 
site within ALR promoter and therefore eliminating its transactivation action 
(chapter 4).  
Furthermore, due to the different etiologies of cholestasis and the possible 
progression into liver cirrhosis and liver failure, exploring potential therapeutic options 
for cholestasis might be of great clinical importance. Interestingly, high levels of 
cytosolic endogenous sfALR (15 kDa) protect hepatocytes from cholestatic injury by 
reducing bile acid synthesis as well as desensitizing hepatocytes to extrinsic-induced 
apoptosis by activating STAT3 (signal transducer and activator of transcription 3). 
Chapter 7  
 
138 
Moreover, ALR expression is reduced in patients with cholestasis due to presumably 
high concentrations of bile acids and inflammatory cytokines (chapter 5). In addition, 
application of recombinant human ALR (rhALR, 15 kDa) contributes to liver 
protection through reducing bile acid synthesis and intrinsic apoptosis (caused by 
accumulation of bile acids in hepatocytes) via activation of NFB (Nuclear Factor 
'kappa-light-chain-enhancer' of activated B-cells) (chapter 6). 
A schematic illustration of bile acid-induced injury and the protective effects of ALR 
found in this thesis are depicted in Fig. 1. 
 
2. Conclusion 
ALR expression is reduced in the liver during cholestatic liver diseases. Furthermore, 
over-expression of sfALR (15 kDa) or application of recombinant human ALR (rhALR, 
15 kDa) alleviate the detrimental effects of bile acids by reducing bile acids synthesis 
as well as reducing bile acid-induced apoptosis. This suggests that attenuated ALR 
expression in cholestasis could contribute to aggravating cholestatic injury. 
Moreover, it proposes the possibility of using ALR as a potential therapeutic agent for 
attenuating the progression of cholestatic liver injury. 
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Fig. 1. Schematic illustration for bile acid-induced injury and the contribution of ALR in attenuating this 
injury. Bile acids accumulate during cholestasis and are imported into hepatocytes by NTCP (Na+-
taurocholate co-transporting polypeptide). Bile acids de-activate IL6 signaling pathway by reducing 
gp130 phosphorylation and the subsequent STAT3 (signal transducer and activator of transcription 3) 
activation. This results in activation of DR5 (death receptor 5) and FASR (FAS receptor) expression 
and increases the number of death receptors on cell surface. Therefore, the cells are rendered more 
susceptible to external death ligands like TRAIL (TNF-Related Apoptosis Inducing Ligand) and FASL 
(FAS ligand) that bind to their receptors (DR5 and FASR respectively) and cause apoptosis. 
Furthermore, bile acids activate SHP which blocks the trans-activation activity of HNF4 and the 
expression of its target genes. Moreover, bile acids activate Egr-1 and induce the expression of its 
target genes ICAM1 (Intercellular Adhesion Molecule 1) and MIP2 (Macrophage Inflammatory Protein 
2) that initiate inflammation. In addition, bile acids indirectly activate Kupffer cells (by IL17 release from 
activated T Helper cells). IL17 activates Kupffer cells and induces the expression and release of pro-
inflammatory cytokines like IL1, IL6 and TNF. In chapter 3 we show that bile acids reduce the 
expression of ALR (hepato-protective factor) (orange arrow) by (i) reduced HNF4 (blocked by SHP) 
and (ii) reduced binding of Egr-1 to its activating binding site within ALR promoter. Moreover, we 
demonstrate the IL1 (released from Kupffer cells) (i) reduces SP1 expression (an activator of ALR 
expression) and (ii) reduces the binding of Egr-1 to ALR promoter which results in reduced ALR 
expression (chapter 4). In addition, the potential protective effects of endogenous short form ALR 
(sfALR) are investigated in chapter 5 (blue arrows). Endogenous sfALR reduces DR5 expression via 
STAT3 activation, and thereby reduces caspase 3/7 activity and apoptosis under cholestatic 
conditions. Endogenous sfALR might also reduce bile acids accumulation by reducing HNF4 
expression and thereby the expression of CYP7A1 (the rate-limiting enzyme of bile acids synthesis) 
and therefore the bile acid pool. Furthermore, recombinant human ALR (rhALR) (pink arrows) binds to 
its receptor and activates the phosphorylation and nuclear translocation of NFB which therefore 
reduces the expression of CAR and reduces the expression of CYP7A1. Moreover, rhALR reduces the 
caspase 3/7 activity and apoptosis initiated by cellular accumulation of bile acids and mitochondrial 
instability without affecting the expression of DR5 (chapter 6). 
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µ Micro (10
-6
) 
Aa Amino acid 
ACLF Acute on chronic liver failure 
ADH1 Alcohol dehydrogenase 1 
AIF Apoptosis inducing factor 
AKI Acute kidney injury 
ALD Alcoholic liver diseases 
ALDH1 Aldehyde dehydrogenase 1 
ALR Augmenter of Liver Regeneration 
ALR-R ALR receptor 
APP Acute phase proteins 
APR Aucte phase responce 
ARE Anti-oxidant response element 
BA Bile acids 
BARE Bile acid response element 
BDL Bile duct ligation 
BNIPL  Bcl-2/adenovirus E1B 
Bp Base pair 
BSEP Bile salt export pump 
C/EBP CCAAT/enhancer binding protein  
CA Cholic acid 
CAR Constitutive androstane receptor 
CCC Cholangiocellular carcinoma 
CCl4 Carbon tetrachloride 
CDCA Chenodeoxycholic acid 
CDH1 E-Cadherin 
cDNA Complementary DNA 
CHOP C/EBP-homologous protein 
CNS COP9 signalosome 
CPT1α Carnitine palmitoyltransferase 1alpha 
CYP2E1 Cytochrome P450 2E1 
CYP7A1 Cytochrome P450 7A1 
CYP27A1 Cytochrome P450 27A1 
DCA Deoxycholic acid 
DMEM Dulbecco’s modified Eagle medium 
DNA Deoxyribonucleic acid 
dnEgr-1 Dominant negative Egr-1 
DR Death receptor 
DTT Dithiothreitol 
e.g. “for example” 
ECL Enhanced chemiluminescence 
EGF Epidermal growth factor 
EGF-R Epidermal growth factor receptor 
Egr-1 Early growth response protein-1 
ELISA Enzyme linked immunosorbent assay 
ELOVL1 Elongation of very long chain fatty acids protein 6 
EMSA Electrophoretic mobility shift assay 
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EMT Epithelial mesenchymal transition 
ERK Extracellular signal regulated protein kinase 
ER-stress Endoplasmic reticulum stress 
Erv1 Essential for respiration and vegetative growth 1 
ESC Embryonic stem cells  
et al. “and others” 
EtOH Ethanol 
FABP1 Fatty acid binding protein 1 
FAD Flavin adenin dinucleotide 
FASR FAS receptor 
FFA Free fatty acid 
FGB Fibrinogen  
FOXA2 Forkhead Box A2 
FXR Farnesoid X Receptor  
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GCA Glycocholic acid  
GCDCA Glycochenodeoxycholic acid  
GDCA Glycodeoxycholic acid 
GFER Growth factor erv1-like 
h Hour 
H/R Hypoxia/reoxygenation  
HP Haptoglobin 
HBV Hepatitis B virus 
HCC Hepatocellular carcinoma 
HCV Hepatitis C virus 
HDAC1 Histone deacetylase 1 
HF Hepatic failure 
HGF Hepatocyte growth factor 
HNF4α Hepatocyte nuclear factor 4 alpha 
HPC Hepatic progenitor cells 
HPO Hepatopoietin 
HPRT Hypoxanthin guanin phosphoribosyl transferase 
HRP Horseradish peroxidase  
HSC Hematopoietic stem cells  
HSS Hepatic stimulator substance 
HTCR Human tissue and cell research 
i.e. “that is” 
ICAM1 Intercellular adhesion molecule 1 
IDD Intrinsically disordered domain 
IHC Immunohistochemistry 
IL Interleukin  
IM Inner membrane 
IMS Intermembrane space  
in vitro lat.: „within the glass” 
in vivo lat.: „within the living” 
IRI Ischemia/reperfusion injury  
JAB1 C-Jun-activating domain binding protein 1 
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JNK C-Jun N-terminal kinase 
Kb Kilo base 
kDa Kilo Dalton 
KO Knock-out 
L Liter 
LC-MS/MS Liquid chromatography-mass spectrometry 
lfALR Long form of Augmenter of Liver Regeneration 
LPS Lipopolysaccharide 
LRH-1 Liver-related homolog-1  
m Milli (10
-3
) 
M Molar 
MAPK Mitogen-activated protein kinase 
MCP1 Monocyte chemoattractant protein 1 
Mia40 Mitochondrial import and assembly 40 
MIF Macrophage migration inhibitory factor 
min Minute 
MIP2 Macrophage inflammatory protein 2 
miRNA micro RNA 
MPT Mitochondrial permeability transition 
mRNA Messenger RNA 
mtDNA Mitochondrial DNA 
NAFLD Non-alcoholic fatty liver diseases 
NASH Non-alcoholic steatohepatitis 
NFB Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
NGS Next generation sequencing 
NK natural killer cells 
Nrf2 Nuclear factor erythroid 2-related factor 2 
nt Nucleotide 
NTCP Na
+
-taurocholate co-transporting polypeptide 
ODC Ornithine decarboxylase 
OMM Outer mitochondrial membrane 
PBS Phosphate-buffered saline 
PCS Portacaval shunt 
PH Partial hepatectomy 
PHH Primary human hepatocytes 
PI3K/Akt Phosphoinositide 3-kinase/AKT 
PKD1 Polycystic kidney disease gene 1 
pSTAT3 Phosphorylated signal transducer and activator of transcription 3 
PTM Post translational modifications 
PVDF Polyvinylidene difluoride 
qRT-PCR Quantitative real-time polymerase chain reaction 
RE Response element 
rhALR Recombinant human ALR 
RLU Relative luciferase unit 
ROS Reactive oxygen species 
RT Room temperature 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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sfALR Short from Augmenter of Liver Regeneration 
SHP Small Heterodimer Partner  
SP1 Specificity protein 1 
STAT3 Signal transducer and activator of transcription 3 
t test Student's test 
tBHQ Tertiary butylhydroquinone 
TCDCA Taurochenodeoxycholic acid  
TGR5 G protein-coupled bile acid receptor 
TLCA Taurolithocholic acid  
TNFα Tumor necrosis factor alpha 
TRAIL Tumor necrosis factor-related apoptosis inducing ligand 
TRX Thioredoxin  
TSPY Testis-specific protein, Y-encoded 
Via lat.: „By way of” 
WB Western blot 
Wt Wild type 
ZO-1 Zona occludens-1 
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Map of pcDNA3.1 vector  
The figure below summarizes the features of the pcDNA3.1 (+) and pcDNA3.1 (-) 
vectors. cDNA sequence of ALR, Egr-1, HNF41, HNF47 and SHP were subcloned 
into pcDNA3.1(+) vectors to generate overexpression vectors (chapter 3 and 
chapter 4).  
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Map of p3XFLAG-CMV (Sigma Aldrich)  
The figure below summarizes the features of the p3XFLAG-CMV vector. dnEgr-1 
sequence was subcloned into p3XFLAG-CMV vector to generate overexpression 
vectors (chapter 3).  
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Map of pGL2-basic vector (Promega)  
The figure below summarizes the features of the pGL2-basic vector. The sequence of 
truncated human ALR promoter were cloned into a pGL2-basic vector.The 
promoterless pGL2-basic vector was used to perform the Luciferase Reporter gene 
Assays (chapter 3 and chapter 4). 
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